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ABSTRACT
Human endogenous sodium pump inhibitors measurement, source, synthesis and regulation

Jie Ma
Department of Chemistry and Biochemistry
Doctor of Philosophy
The sodium pump (SP or Na+,K+-ATPase) is a membrane embedded protein complex that
pumps 3 sodium ions out and 2 potassium ions into the cell per cycle and in so doing creates a
cell membrane electrochemical potential. The membrane potential is critical for any functional
cell. In the vasculature, reduction in the voltage potential causes vascular smooth muscle
contraction and a narrowing of blood vessels (vasoconstriction) which can lead to increased
blood pressure (hypertension). Substantial research over the past several decades has provided a
vast amount of research on SP inhibitors, sometimes called endogenous digitalis-like factors
(EDLF). Increased levels of these factors have been implicated in many hypertensive disorders
including preeclampsia (PE), a life-threatening complication of pregnancy. It has been
demonstrated that EDLF might be a causative factor in the pathophysiology of hypertension in
PE. In order to elucidate EDLF production and regulation in PE, We developed a
radioimmunoassay (RIA) measuring EDLF that could be applied to serum from pregnant women,
placental homogenate and placental tissue culture. This assay employs Digibind, a commercially
available Fab fragment derived from polyclonal antidigoxin antibodies that cross reacts with
EDLF, as the primary antibody. Using Digibind RIA, we demonstrated that placenta is a source
of EDLF production and regulation. Moreover, the identification of an inhibitor, ketoconazole
and a substrate, 17-hydroxyprogesterone of the synthetic pathway of EDLF in placenta proved
that this pathway shares steps with the steroid synthetic pathway. Some potential regulatory
agents which have elevated levels in PE or be associated in PE and thus are thought to mediate
PE, such as hydrogen peroxide, tumor necrosis factor- (TNF-) and hypoxia have also been
demonstrated to be stimuli of EDLF production in placenta. These findings are helpful to the
further study on EDLF synthesis and regulation in placenta. Once we elucidate the mechanisms,
it could be easier to provide deeper insights into the pathogenesis of PE and subsequently
develop earlier diagnosis and effective prevention of or therapeutic approaches to PE.

Keywords: sodium pump, preeclampsia, digoxin (digitalis), endogenous digitalis-like factor
(EDLF), Digibind
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Chapter 1: Introduction

The sodium-potassium pump or simply the sodium pump (SP) (also known as the Na+,K+ATPase) is a highly-conserved protein complex embedded in the plasma membrane in all cells of
higher organisms. It pumps three sodium ions out and two potassium ions into the cell per cycle
and creates a cell membrane electrochemical potential, which is the basis for excitability in nerve
and muscle cells (Fig 1). For most animal cells, the SP is responsible for 1/3 of the cell‟s energy
expenditure. For neurons, the SP is responsible for 2/3 of the cell‟s energy expenditure. In
addition, the sodium gradient resulting from export of sodium ions from the cell provides the
driving force for several facilitated transporters, which not only import glucose, amino acids and
other nutrients into the cell but also export calcium ions out of the cell1. For example, SP
reduction causes reduction in the cell membrane voltage potential (depolarization) as well as an
insufficient driving force for Na+ entry into the cell through the Na+-Ca2+ transporter, resulting in
a Ca2+ entry and accumulation of intracellular calcium. In vascular smooth muscle (VSM) cells,
increased concentration of calcium leads to contraction with a narrowing of blood vessels
(vasoconstriction). Excessive vasoconstriction increases peripheral resistance and then results in
high blood pressure (hypertension). In the heart, increased intracellular calcium causes heart
muscle contraction2.

Molecular studies have revealed that the SP, possesses 8 or 10 transmembrane domains, is
composed of an subunit (~113KD) and a glycosylated  subunit (~35KD) which combine to
form the functional transporter1. The  subunit comprises important functional domains that
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undergo a series of conformational changes, bind sodium and potassium ions, and contains the
phosphorylation site. The  subunit is critical in facilitating the plasma membrane localization
and activation of the  subunit3. Several isoforms of both  and subunits have been identified,
including 1, 2, 3, 4, 1 and 2, which have both tissue and species specific distribution as
well as functional implications. Northern and western blot analyses carried out by our and other
laboratories confirmed that in the kidney, the 1-isoform is the dominant form of the  subunit,
in skeletal muscle and vascular smooth, the 2- isoform is prominent, the 3-isoform exists
predominantly in fetal brain and adult neural tissues. In the heart, all of the 1-, 2- and 3isoforms are present, whereas the 4-isoform has only been detected in testis and sperm4, 5, 6.
These isoforms of the subunit display distinct sodium affinities as well as sensitivities to
cardiac glycosides, such as digoxin and ouabain. For example, the 1-isoform has the highest
affinity for sodium ions but has a distinctly lower affinity for ouabain than the other two
isoforms, in particular in rat and mouse tissues. Therefore alterations in the SP isoform
distribution accompany hypertensive conditions4, 5, 7.

The mechanism of active SP ion transport is driven by the breakdown of ATP. With bound
ATP, the SP binds three intracellular sodium ions. ATP hydrolysis leads to phosphorylation of
the SP, and then induces a conformational change in the pump, which translocates the sodium
ions across the membrane. The new conformation has a low affinity for sodium ions and a high
affinity for potassium ions, so the three bound sodium ions dissociate from the pump and diffuse
into the extracellular fluid and two potassium ions bind to the extracellular side of the pump.
This causes the dephosphorylation of the SP, reverting it to its original conformation,
transporting the potassium ions to the cytoplasm on the inside of the cell. This unphosphorylated
2

form of the SP has a low affinity for potassium ions, so the two bound potassium ions dissociate
from the pump and diffuse into the interior of the cell (Fig 2). The SP then starts a new cycle by
binding ATP1.

The SP can be regulated in several ways and in both acute and chronic timeframes: Its
genetic production can be increased or decreased by transcription factors. Its activity can be
modified by the SP being phosphorylated or dephosphorylated, often in response to hormones
binding to the cell with activation of intracellular kinases. For example, it has been
demonstrated that dopamine, a SP inhibitor, inhibits SP activity by stimulating protein kinase C
(PKC), and this dopamine-induced SP inhibition
defined intracellular compartments in rat renal tubule cells8. We also studied the endocytosis of
SP in response to dopamine as well as other regulators in myometrial cells, the main muscle cells
of uterine wall, using confocal microscope and immunofluorescence. A final mechanism of
regulation, one of particular interest here, is the presence of inhibitors produced by the body
which can decrease the activity of the SP9. Such inhibitors have also been identified in plants, in
particular the common foxglove plant Digitalis purpurea, which has been used therapeutically
for over 200 years as a cardiac glycoside. Compounds derived from the foxglove leaf, e.g.
digoxin (also known as digitalis) and digitoxin, are widely used in the treatment of congestive
heart failure, atrial fibrillation, atrial flutter and some heart failure that cannot be controlled by
other medication. For example, congestive heart failure is a common disease among the elderly
in that the heart demonstrates a reduced ability to compress its chambers which reduces the
output of the heart. Digoxin and related compounds have been used to treat this condition
effectively by binding to a site on the extracellular aspect of the -subunit of the SP in heart cells
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(myocytes) and inhibiting its SP activity. As described above, inhibition of SP causes a rise in
the level of intracellular sodium ions, which in turn slows down the extrusion of calcium ions or
even induces depolarization of the cell membrane with calcium entry through voltage dependent
calcium channels in the heart and through the Na+-Ca2+ transporter that relies on the high sodium
gradient in vascular smooth muscle. Increased amount of calcium in the cardiac myocytes leads
to increased contractility of the heart and the subsequent increased stroke volume.

However, one of the challenges in using digoxin is that it can be very toxic at
concentrations only slightly above those therapeutically needed. Digoxin overdose has been a
relatively common problem and has led to the development of an antibody fragment called
Digibind® that binds digoxin and eliminates its toxicity10. Digibind is a commercially available
Fab fragment derived from polyclonal antidigoxin antibodies raised in sheep. It has been shown
to be effective and safe in treating digoxin overdose or digitalis glycoside toxicity by binding
digoxin and making it unavailable for binding to the SP in the organism generally. The Digibinddigoxin complex accumulates in the blood, from which it is excreted by the kidney. The net
effect is to shift the equilibrium away from binding of digoxin to its receptors (SP) in the body,
thus reversing its effects.

Because some diseases appear to be related to SP inhibition, substantial research over
the past several decades has provided a vast amount of research on SP inhibitors, collectively
referred to as endogenous "digitalis-like" factors (EDLF) which have been found in several
tissues and body fluids of animals and humans. These EDLFs are the primary research subject
here. EDLFs are compounds with biological and immunological properties similar to cardiotonic
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drugs, such as digoxin. They cross-react with digoxin antibodies and inhibit SP by binding to the
same binding site as used by digoxin. Therefore, the factors may be identical to or structurally
related to digoxin or ouabain, but the exact structure of this factor or factors is unknown.
Increased levels of these factors have been implicated in many hypertensive disorders. The
reasons for these EDLFs being increased is unclear but there is overwhelming data to show that
the levels of EDLF are increased in serum in human essential hypertension, many secondary
forms of human hypertension and many experimental animal models of hypertension, suggesting
that increased levels of EDLF may be a causative factor in the pathogenesis of hypertension11.
Moreover, in experimental models of hypertension with elevated EDLF levels, Digibind
administration has been demonstrated to lower or even normalize blood pressure. Serum from
individuals with hypertension has been shown to inhibit the SP in isolated red blood cells (and a
variety of other peripheral blood cells and some tissues) and to increase vasoconstriction of
isolated blood vessel rings, which effect could be prevented or reversed by the presence of or
addition of Digibind12. Previous studies also demonstrated that renal arteries from hypertensive
animals had increased levels of intracellular sodium ions as well as reduced SP activity, and
these effects could also be reversed by Digibind13. These observations indicated that EDLFs are
involved in hypertension by inhibiting the SP and Digibind can reverse the effect by binding and
blocking these factors.

My research has focused on preeclampsia (PE), which is one of the hypertensive
disorders related to EDLF. It may now be the number one killer of pregnant women in the world
and more often occurs with first pregnancies after 20 weeks gestation. Hypertension, proteinuria,
swelling, sudden weight gain, headaches and changes in vision are important symptoms. Less
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than one in 100 women with preeclampsia will develop eclampsia or seizures. PE may initially
involve generalized damage to the maternal vascular endothelium, sometimes affecting kidneys
and liver, with the release of vasopressor factors secondary to the original damage. Additionally,
PE is a leading known cause of iatrogenic preterm birth. The unborn baby in preeclamptic
pregnancy can suffer prematurity, intrauterine growth restriction (IUGR), acidosis and even
death. At present, the causes and pathophysiology of the disease are still poorly understood,
partly because that PE is multi-factorial in nature, involving vascular, genetic, immunological
and/or environmental factors. In fact it may have several causes all of which lead to a final
common pathway. Hence, there is no direct way to test if or when PE will occur, and no
treatment to prevent or treat PE. When it is severe, even if it occurs early in the pregnancy, the
only cure is to deliver the fetus in order to protect the life of the mother. Therefore more
effective therapies to protect the mother while allowing the baby to grow and develop are
important14.

Multiple abnormalities have been reported in PE and as described above, one of the
abnormalities is an elevation in the circulating levels of EDLF. Although elevated levels of these
factors are found both in normal pregnancy and in pregnancy complicated by PE, the levels in
PE are significantly higher than in normal pregnancy. Given its ability to cause vasoconstriction,
EDLF might play a role in the pathophysiology of PE. In vitro experiments demonstrated that
reduction in SP expression in PE may raise level of intracellular sodium ions or increase pressor
sensitivity, which contributes to hypertension in PE15. Clinical trials also showed that for
preeclamptic women, treatment with Digibind reduced patients‟ blood pressure dramatically.
These observations support the hypothesis that Digibind might improve some of the symptoms
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of PE by binding with the SP inhibitor--EDLF, especially hypertension and Digibind could be a
potential therapy for women with PE. Therefore, the aim of this study is to elucidate mechanisms
of EDLF production and regulation in PE. This work may provide insights into how to interrupt
production of EDLF as a possible further therapeutic approach to PE.

It is believed that EDLF is structurally very like the steroidal glycoside digoxin or an
analogue with an unsaturated lactone ring and that it is synthesized by the isoprenoid pathway, a
very complex route that involves multiple steps (Fig 3) or from cholesterol in the diet. The
isoprenoid biosynthetic pathway is a key regulatory pathway generating a high number of endproducts essential for cell viability such as cholesterol, sterols, dolichols, coenzyme Q, heme and
prenylated proteins16. However, because the structures of EDLFs have not been completely
identified and the isoprenoid pathway involves diversified metabolites, mechanisms of EDLF
synthesis and regulation are not clear. For this research key intermediates of an endogenous
digoxin pathway would be of interest.

We hypothesized that some intermediates of the isoprenoid pathway, pregnenolone,
progesterone and progesterone derivatives such as 17-hydroxyprogesterone, may be used to
generate the EDLF (Fig 4). To verify the hypothesis we tested the effect of 17hydroxyprogesterone on EDLF production. Increased EDLF levels with the presence of 17hydroxyprogesterone in placental tissue culture will indicate that this substance contributes to
EDLF synthesis and might be a substrate of EDLF biosynthetic pathway.
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On the other hand, ketoconazole, an imidazole derivative, and a general inhibitor of P450
dependent enzymes, has been proven to block gonadal and adrenal steroidogenesis in humans17.
Moreover, it was also found to inhibit cholesterol synthesis by blocking the conversion of methyl
sterols to cholesterol18. Therefore, ketoconazole would be predicted to be an inhibitor of EDLF
synthesis pathway if EDLF synthesis uses enzymes that are part of steroid synthesis. Our
experimental data showed that it significantly reduces EDLF levels in placental tissue culture,
which is consistent with the hypothesis.

Besides elevation in EDLF levels, there are some other abnormalities reported in PE,
including reduced uteroplacental perfusion, hypoxia, higher levels of reactive oxygen species
(ROS), defective trophoblast differentiation and invasion of the decidua, altered placental
production of cytokines and growth factors, and endothelial dysfunction, which are also
considered to be important aspects in the etiology of PE19. Studies during the past decade have
provided a better pathophysiologic understanding of PE. Currently, etiologic hypotheses of PE
focus on maladaptation of immune responses and impaired trophoblast invasion. What is most
widely accepted is that reduced uteroplacental perfusion (superficial implantation of the fetus)
due to inadequate invasion of the maternal uterine spiral arterioles into the placental trophoblast
is an important initiating event in PE. Poor placental perfusion leads to placental and fetal
hypoxia. Oxygen plays a central role in human placental pathologies, and hypoxia results in
widespread activation and dysfunction of the maternal vascular endothelium via altering
production of pro and anti-inflammatory cytokines and cytokine-like angiogenic growth factors.
Endothelial dysfunction then enhances formation of vasoconstrictors such as endothelin and
thromboxane, increases formation of superoxide and vascular sensitivity to angiotensin II (a
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potent hypertensive agent), and reduces formation of vasodilators such as nitric oxide and
prostacyclin. These endothelial alterations eventually cause hypertension through increasing
vascular resistance and impairing renal function19, 20, 21, 22. However, the actual cause of
hypertension is unknown. For example, therapeutics that reduced thromboxane while increasing
prostacyclin had absolutely no effect of the incidence or severity of PE.

PE is widely believed to be associated with placental hypoxia. During pregnancy,
hypoxia induces endothelial dysfunction by activating oxidative stress, which then promotes
intrauterine growth retardation, one of the features of PE. Oxidative stress is an excess formation
and/or insufficient removal of ROS, such as hydroxyl radical, superoxide anion, hydrogen
peroxide and singlet oxygen23. There is increasing evidence supporting that hypoxia-induced
oxidative stress may be an important contributing factor to the pathogenesis of PE. Compared
with healthy pregnant women, preeclamptic women have higher levels of ROS and lower levels
of several dietary antioxidants in their blood, including vitamin C and E, lycopene and
betacarotene. Elevated levels of markers of oxidative stress, such as lipid peroxides (Fig 5) have
also been observed in the placenta and circulation of preeclamptic women. ROS have been
demonstrated to play a pathophysiological role in the development of hypertension in PE in some
studies. Overproduction of ROS destroys endothelium-derived nitric oxide in vitro and decreases
its bioavailability, resulting in impaired endothelium-dependent vasodilatory response and
increased vascular resistance, and consequently could cause hypertension24, 25. However, there
have been several very large studies that have supplemented pregnant women with high intake of
both fat soluble and circulating antioxidant vitamins without any effect on the incidence or
severity of PE. However, the issue of hypoxia and ROS may be much more localized to the
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placenta and its immediate environment. Since both ROS and EDLF may be involved in
preeclamptic hypertension, we are interested in their relationship in the pathology of PE. Do
ROS induce hypertension through regulating EDLF biosynthesis? Is hypoxia-induced oxidative
stress a mediator of EDLF and represent linkage that contributes to the hypertension in PE?
Knowing the role of hypoxia or ROS and EDLF synthesis and release would be helpful to
elucidate potential pathogenesis of PE and the interplay of different systems that may lead to
hypertension. Therefore, we carried on a series of in vitro experiments testing the effects of
hypoxia and hydrogen peroxide on EDLF production. The results showed that both hypoxia
treatment and addition of hydrogen peroxide into the placental tissue culture lead to increased
EDLF levels in the culture, suggesting that hypoxia and ROS might be regulatory factors of
EDLF production.

The cytokines produced by the placenta are involved in maternal immune response and
also have a role in fetal development. Recently, substantial evidence supports that cytokines and
other factors such as lipid peroxides and ROS are potential mediators of endothelial
dysfunction26. Endothelial tissue is a specialized type of epithelial tissue that is highly active and
closely involved in numerous physiological processes. Endothelial cells, lining the entire
circulatory system, from the heart to the smallest capillary, are believed to participate in
angiogenesis, adaptation of vascular tonus and maintenance of blood fluidity in the
microcirculation. It has been demonstrated that endothelial dysfunction has prognostic
significance in predicting vascular events, including stroke and heart attacks; in particular it‟s a
central pathophysiological feature in the maternal vascular system in PE27. Oxidative stress and
altered immune response at the fetal-maternal interface are thought to be contributors of the
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development of endothelial and renal dysfunctions in PE. And inflammatory cytokines are
believed to link placental hypoxia with maternal endothelial abnormalities and cardiovascular
and renal dysfunction. Hence, interactions between placental cytokines and the maternal
endothelium might play a central role in the pathogenesis of PE20, 26, 28.

As described above, shallow trophoblast invasion, the proposed initiating event in PE,
may induce an excessive maternal inflammatory response, which results in a chain of events
including increased circulating levels of cytokines, such as tumor necrosis factor- (TNF,
interferon-(IFN) and interleukin-6 (IL-6). Elevated levels of TNF and IL-6 have been
detected in the circulation of preeclamptic women29. Since convincing evidence showed that
cytokines have an impact on vascular function and endothelium-derived factors involved in
blood pressure regulation, and Digibind attenuates TNF-induced inflammatory response in
endothelial cells, we hypothesized that cytokines, especially TNF, might be involved in
regulation of EDLF synthesis and release30, 31. TNF may influence blood pressure indirectly
through regulating EDLF levels, and Digibind reduces these effects by binding with EDLF. In
order to verify our hypothesis and elucidate the mechanisms of regulation of EDLF synthesis
pathway, we designed experiments to identify the role of TNF in EDLF production and release.
The data indicated that TNF induce elevation in EDLF levels in placental tissue culture and it
might be a regulatory agent that upregulates EDLF biosynthesis pathway.

These studies should greatly clarify the synthetic pathway of EDLF and help us
understand the interrelationship of systems thought to play a significant role in the early events
leading to the clinical condition we know as PE.
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Figure 1. How the SP works. It moves Na + out and K+ into cells and generates the cell membrane potential32.
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Figure 2. Mechanism of a cycle of active SP. A SP inhibitor, such as ouabain, locks the enzyme in its
phosphorylated state and prevents further cycling of the SP. This causes Na+ to accumulate in the cell and
depolarizes the cell membrane leading to increased Ca2+ in the cytosol and in turn to VSM contraction32.
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Figure 3. Steroidogenesis by Mikael Haggstrom, showing many enzyme activities of cytochrome P450 enzymes 33.
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Figure 4. Structures of analogues of EDLF: digoxin and ouabain, and potential substrates of EDLF synthesis:
progesterone, 17-hydroxyprogesterone, aldosterone and cortisol.
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Figure 5. Mechanism of lipid peroxidation. The initiators in living cells are always reactive oxygen species (ROS),
such as OH-, which combines with a hydrogen atom to generate water and a fatty acid radical. The unstable lipid
radical reacts readily with oxygen and produces a lipid peroxyl radical, which is also an unstable molecule, reacting
with another free fatty acid and generating a different lipid radical and a lipid peroxide if it had reacted with itself.
The cycle continues until two radicals react and produce a non-radical species34.
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Chapter 2. Sodium Pump Endocytosis in Human Myometrial Cells in Response to its
Inhibition

Introduction

The sodium pump (SP, also called [Na,K]ATPase) undergoes complex regulation which
has been studied for several decades. Several ways are available to govern its abundance and
activity. These include effects of the genomic expression of the SP. For example aldosterone, a
mineralocorticoid steroid, has present in the cytosol with a nuclear receptor. When aldosterone
is increased in the circulation, it can diffuse through cell membranes and combine with its
protein receptor. The complex is moved into the nuclear compartment with the complex where it
binds to the hormone response elements on the gene(s) coding for the α subunit of the SP thereby
increasing its transcription and expression. These events require hours to days to be fully
manifest.

In addition, the activity of the SP can be altered by phosphorylation or
dephosphorylation of the α subunit protein. Typically, phosphorylation leads to reduced activity
and conversely dephosphorylation is typically associated with marked increases in activity. The
effect depends on which amino acid is phosphorylated. An example of this is dopamine which
binds to a cell surface receptor initiating a cascade of intracellular events typified by the
activation of kinases or phosphorylases which add or remove phosphate groups to several
proteins, including the SP. These events are rapid, occurring in minutes.
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There are other means of regulation. In some cell types some hormones may activate
their receptors which in turn can lead to the removal of the SP from the cell membrane, for some
in consequence of SP phosphorylation. For example, substantial evidence showed that in renal
tubule cells, SP inhibition by dopamine involves endocytosis of SP - and - subunits1, and this
inhibition is associated with prior phosphorylation of the  subunit2.

Another significant means of SP regulation is the presence of specific inhibitors.
Structurally, all specific SP inhibitors are sterols with an unsaturated lactone ring coupled to the
D ring of the steroid backbone. These are typically circulating inhibitors that bind to an external
domain of the SP α subunit with high binding affinity. Not only do these inhibitors produce
immediate disruption of the inotropic activity of the SP they also appear to cause SP endocytosis.
This has been demonstrated using Western blot analysis of the SP but also using fluorescence
imaging and conventional biochemical and biophysical cell separation methods3.

In these studies efforts were made to clarify and specify the processes that are involved in
SP removal from the cell membrane in response to SP inhibition or the application of dopamine,
both of which have shown to cause SP removal from the cell membrane. Little information was
available about the location of the SP within the cell, in particular the specific organelles used,
and whether the pathway was similar to that described for other endocytotic events. Myometrial
cells were used to study SP endocytosis in response to the SP inhibitors. The myometrium is the
middle layer of the uterine wall which supports stromal and vascular tissue and induces uterine
contractions. Myometrial cells are smooth muscle cells rich in the SP. However, primary
cultures of myometrial cells have a limited life span. Studies demonstrated that cell culture life
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span is related to chromosomal telomere length, and cellular senescence results from progressive
telomere shortening and the lack of telomerase expression. Therefore, in order to have continual
cell lines, we used telomerase immortalized myometrial cells transfected with human telomerase
reverse transcriptase (hTERT) which maintains telomere length and effectively gives normal
human myometrial cells an unlimited life span in culture4.

In order to clarify the changes of SP in response to the inhibitors, we used two approaches.
The first used gradient ultracentrifugation to isolate specific organelles before and after exposure
to the SP inhibitor ouabain or to dopamine a second agent demonstrated to cause SP removal
from the cell membrane. As a second line of evidence we attempted to use confocal microscopy
to visualize myometrial cells and potentially subcellular mapping of the SP to organelles treated
by ouabain, dopamine or lipopolysaccharide (LPS), another SP inhibitor.

Confocal imaging was invented by Marvin Minsky to overcome some limitations of
traditional wide-field fluorescence microscopes in 1957. Conventional fluorescence microscopy
images directly and the entire specimen is flooded evenly with light from a lamp. Hence, all
parts of the specimen in the optical path are excited at the same time and the resulting
fluorescence is detected by the microscope‟s photodetector or camera, including a large area of
unfocused background. In contrast, confocal microscopes use point illumination and a spatial
pinhole in an optically conjugate plane in front of the detector to eliminate out-of-focus signal.
By scanning one or more focused beams of light, usually from a laser, across the specimen, the
point of illumination is brought in focus within the specimen, and laterally scanned under
computer control. This technique enables the reconstruction of three-dimensional structures
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from the scanned images. Therefore, it is a sophisticated way of analyzing both the inside and
outside of cells and has been widely applied in life sciences, semiconductor inspection and
material science.

Methods
Cell Culture
Preserved cultures of telomerase immortalized human myometrial cells were taken (~1.5
mL/tube) from the cryo liquid nitrogen, and the tube of cells thawed in 37˚C water bath until
there was only a little ice left. Gently, 0.5 mL of the cells were introduced into a culture plate
containing 10 mL of warm Dulbecco‟s Modified Eagle Medium: Nutrient mixture F-12
(DMEM/F12, Invitrogen, Carlsbad, CA, USA) containing 10% Fetal Bovine Serum (FBS,
Gibco, Carlsbad, CA, USA) and 0.1% gentamicin (Sigma, St. Louis, MO, USA). The cells were
cultured in an incubator at 37˚C and were checked for cell adherence next day. If the cells
started to adhere, the medium was exchanged with fresh medium and incubated at 37˚C until cell
confluence reached 75-80%, a growing stage which could be passaged with 1:100 trypsin. The
culture medium was changed every 2 days to make cells grow well.

Gradient Ultracentrifugation
Sucrose Density Gradient Preparation
5%, 13.75%, 22.5%, 31.25% and 40% of sucrose solution were prepared. 950 L of each
sucrose solution were added in Beckman SW55 Ti rotor tubes sequentially and slowly using a
large bore pipette tip (cut off approximately 2 mm from the tip of a 1 mL pipette tip). The tube of
sucrose solution layers was kept at 4˚C overnight to form a linear gradient.
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Cell lysis and fluorescence label
-80% confluent myometrial cells and the cells
were continued to be incubated in the incubator at 37˚C for 2 hrs or 12 hrs. A 10 L of sample of
miliQ H2O was added to one plate as a control. After incubation, cells were harvested and lysed
in 0.5 mL of homogenization buffer (pH 7.4) containing 250 mM sucrose, 0.5 mM EDTA and 3
mM ididazole at -80˚C overnight. The lysed cells were then stroked in a glass homogenizer for 5
times. The lysate were centrifuged at 1000Xg for 5 min at 4˚C. Supernatant were obtained and
incubated with 10 L of rabbit anti-Rab5 (early endosome antibody, 1:100, Abcam, Cambridge,
MA, USA) or goat anti-Rab7 (late endosome antibody, 1:100, Abcam, Cambridge, MA, USA)
on a shaker at 4˚C overnight. After incubation, 10 L of 1:100 Alexa Fluor® goat anti-rabbit IgG
(Invitrogen, Eugene, OR, USA) or Alexa Fluor® Donkey anti-goat IgG (Invitrogen, Eugene, OR,
USA) was added into the lysates and the mixture was put on ice for 2 hrs.

Ultracentrifugation
solution
and centrifuged at 4˚C for 4 hrs at 50,000 rpm. After centrifugation, carefully transfered 300 L
of fractions from the top of the gradient to microcentrifuge tubes with large-bore pipette tips.

Fractions were detected for fluorescent intensities using a fluorometer (ISS, Champaign,
IL, USA).

Cell fixation and fluorescence label
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Regulatory factors treatment
Confluent myometrial cells were passaged into 4-well Lab-Tek chamber (0.8 mL/well,
NUNC, Rochester, NY, USA) and incubated at 37˚C overnight for ~80% confluence. The
culture media was exchanged and 2 L of 0.4 mM ouabain or dopamine solution (final
concentration 1 M) or 1.6 L of 500 ng/L LPS was added to the wells respectively and they
were incubated at 37˚C for 5 min, 10 min and 15 min. A 2 L sample of miliQ H2O was added
to one well as a control. The chamber was put on ice to terminate incubation.

Cell fixation
Culture media was removed from the wells and the adherent cells were washed gently with
0.4 mL of PBS per well. 200 L of 4% para-formaldehyde were added to each well and the
whole chamber was incubated on a rocker at speed 2˚ for 30 min at room temperature. Paraformaldehyde was then removed and the wells were washed with 400 L of PBS for 5-10 min
with gentle rocking 3 times.

Blocking
300 L of PBS-Triton (PBT, 1XPBS, 0.1% Triton x-100) containing 5% FBS was added
to each well to block non-specific binding sites. The chamber with blocking solution was
incubated on a rocker at speed 2˚ at room temperature for 30 min.

Primary Ab incubation
Mouse monoclonal anti-SP 3 Ab IgG (ABR, Golden, CO, USA) was used as the
primary Ab. 1 L of 1˚ Ab in 300 L of PBT containing 2% FBS were added into each well and
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the chamber was covered and incubated overnight at 4˚C. After incubation, the 1˚ Ab with PBT
was then removed and the wells were rinsed 3X5 min each in PBT.

Secondary Ab incubation
BODIPY® labeled goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA) was used
as the secondary Ab. 1 L of the 2˚ Ab in 300 L of PBT containing 2% FBS were added to
each well and the chamber was incubated for 2 hrs at room temperature. After incubation, the 2˚
Ab with PBT was removed and the wells were rinsed 3x for 5 min each with PBS. The wells
were air dried. Photos of the fixed cells treated with ouabain/dopamine/LPS were taken by
confocal microscope (Olympus FV300 confocal laser scanning biological microscope, 40X).
These experiments were carried out ~5 times to find out the optimal concentration and treatment
time of the inhibitors.

Besides the above method, we made a lot of attempts to try other Abs and dyes to
optimize the assay. For example, we used BODIPY® labeled ouabain (1.6 L of 500ng/L per
well, Molecular Probes, Eugene, OR, USA) to treat myometrial cells and took images using
confocal microscope; we also treated cells with ouabain/dopamine, and then used an early
endosome Ab anti-Rab 5B (1 L of 1g/L, Santa Cruze, CA, USA) and an late endosome Ab
anti-MPR (5 L of 0.2 g/L, Chemicon, Billerica, MA, USA) as the primary Ab respectively,
and used Alexa Fluor® 546 goat anti-mouse IgG (Invitrogen, Eugene, OR, USA) as the
secondary Ab to fluorescence-labeled the endosomes to track their relocation. Similarly, we did
~5 times for each experiment to try different concentrations and treatment time.
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Results
The data from sucrose density gradient ultracentrifugation showed that with either 2 hr or
12 hr treatment of ouabain, SP abundance in endosomes increased. Obviously, with 2hr
treatment SP in early endosome (EE) were more than in late endosome (LE) (Figure 6), but less
than in LE after 12hr treatment (Figure 7). These results indicate that SP relocated in myometrial
cells after treated by ouabain and the movement is time dependent.

Figure 6. 2hr effect of ouabain on SP abundance in early and late endosomes. Ouabain treated myometrial cells
were labeled using early endosome (EE) and late endosome (LE) fluorescent makers and cellular organelles were
isolated using sucrose density gradient centrifugation. SP abundance was determined by fluorometer.
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Figure 7. 12hr effect of ouabain on SP abundance in early and late endosomes. Ouabain treated myometrial cells
were labeled using early and late endosome fluorescent makers and cellular organelle were isolated using sucrose
density gradient centrifugation. SP abundance was determined by fluorometer.

We used dopamine, ouabain and LPS to treat cultured human myometrial cells. In order to
reduce the background fluorescence, we fixed the cells in the well of the chamber using paraformaldehyde, and then used fluorescence labeled antibodies to bind with the -3 subunit of the
SP (At the beginning, we carried out some experiments without the cell fixation and blocking
steps. This made the background of the images very high and the fluorescence inside the cells
was not obvious enough to be identified).
Bodipy labeled antibody (Ab) anti-SP-subunit appeared to perform better than other Abs and
dyes. Images collected by confocal microscopy showed that the addition of both dopamine and
ouabain changed cells‟ shape, specifically caused the elongated uterine smooth muscle cells to
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shorten or contract (Figure 8). Notice that cells treated with dopamine (the middle image) and
ouabain (the bottom image) became round and short compared with the control cells to which
only miliQ H2O2 was added. They appear long and narrow in the top image. Moreover, the
inhibitors also induced uniform fluorescence intensities, indicating that these inhibitors could
result in SP endocytosis. Ouabain appeared to induce more changes in the SP, both in the shape
and the relocation of the SP within the cell. LPS did not show any obvious effects on
myometrial cells or the SP in myometrial cells using confocal imaging (not shown). This
suggests that LPS inhibits SP activity in a different way.
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Figure 8. Comparison of effects of dopamine and ouabain on myometrial cells. Pictures were taken by confocal
microscope. Top: fixed myometrial cells without treatment; Middle: myometrial cells treated with dopamine for 15
min were fixed and photographed; Bottom: myometrial cells treated with ouabain for 15 min were fixed and
photographed.
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After we knew that ouabain could induce the greatest amount of endocytosis of SP
subunit, we were interested in the sequence of events for SP removal and translocation within
the cell. Hence, we carried out time dependent experiments. We treated myometrial cells with
ouabain for different times of exposure and then took pictures using the confocal microscope.
Figure 9 showed that with longer ouabain exposure, the cells appeared to demonstrate greater
changes. The fluorescence moved from the edge of the cells to the inside gradually, making the
fluorescent intensities more uniform little by little. It suggested that ouabain-induced SP
endocytosis is time-dependent. However, the imaging did not allow us to clarify where the
removed SP was then located. The magnification available with this instrument was not
sufficient to allow this.
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Figure 9. SP regulation in response to ouabain. Pictures taken by confocal microscope showed changes of
myometrial cells treated by ouabain with different time (top left: without ouabain, top right: 5 min ouabain treatment,
bottom left: 10 min ouabain treatment, and bottom right: 15 min ouabain treatment). Longer time ouabain treatment
induced more changes of cells‟ shape and more uniform fluorescent intensity.

Our results using confocal microscopy were promising. We verified that not only
dopamine, but also ouabain could induce SP  subunit endocytosis, and this effect was timedependent. The changes in cell shape appear to be related to the contraction of the myometrial
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smooth muscle cells, consistent with the finding that SP inhibitors lead to uterine contraction.
However, due to the poor resolution of the confocal microscope we used, it was hard to further
study how the inhibitors induced SP endocytosis, especially the intracellular location of the SP.
Eventually, the myometrial cell cultures in our lab were contaminated and additional sample of
the immortalized human myometrial cells were unavailable. Finally the project could not be
continued.
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Chapter 3: Development of a Theranostic for PE

Introduction
The recent idea of individualized medicine relies on the concept that one can measure
biochemicals or genetic information in one patient‟s body and by knowing this the health care
provider can tailor treatment appropriately. This approach has been used successfully for
decades for bacterial infections. Culture of specimens then leads to the identification of the
specific bacterial organism causing an infection which then dictates which antibiotic to use to
insure effective treatment.

More recently, gene analysis has allowed for the identification of specific gene alleles that
carry with them a very substantial risk for the later development of breast cancer1. Women
having this genetic makeup are encouraged to undergo aggressive therapy, including
mastectomies, prophylactically to prevent the occurrence of the cancer2.

It is well accepted that preeclampsia is a syndrome, representing a common clinical
endpoint but having more than one cause. In reality none of the proposed etiologies for PE is
proven although substantial data suggest the involvement of one or more specific pathologic
pathways as the disease progresses. Hence, PE would be an ideal medical target for more
specific, rational therapies.

One of the proposed abnormalities in PE that may mediate the increased blood pressure that
is a hallmark of PE is the presence of increased levels of a sodium pump inhibitor(s), referred to
as endogenous digitalis-like factor or EDLF3. The reference to digitalis is based on many studies
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indicating similar biological activity and chemical structure of the EDLFs to known plantderived cardiotonic steroids derived from the digitalis plant. The involvement of these factors in
the hypertension of PE has been well enough documented to actually suggest that counteracting
EDLFs might improve the maternal features of PE to the extent of prolonging the pregnancy,
increasing the viability of the fetus while maintaining a stable maternal condition4, 5.

Laboratory data have demonstrated that antibodies directed at digoxin, the most commonly
used Digitalis cardioglycoside, reversed the effects of both known plant derived sodium pump
inhibitors and EDLFs6, 7. In particular, a digoxin specific antibody Fab fragment named
Digibind, used in the treatment of digoxin toxicity, was able to bind and inactivate many, if not
most, EDLFs8, 9. These laboratory data, which included demonstrations of Digibind having antihypertensive effects in experimental animal models of essential hypertension7, along with a good
safety profile for Digibind in individuals treated for digoxin overdose10, led to the use of
Digibind in a few preeclamptic women on a compassionate use basis4, 5.

These in turn led to a randomized, double blind, clinical trial of Digibind in preeclamptic
women in the immediate post partum period11. This study demonstrated that women receiving
drug required significantly less anti-hypertensive therapy and had faster falling blood pressures
than the control preeclamptics receiving placebo.

Based on laboratory data, the incidental use of Digibind in preeclamptics (PE) and the
results of the post partum clinical trial led to a FDA approved Phase II clinical trial of Digibind
in severe PE11. This was designed as a multi-center, randomized, double-blinded clinical study
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termed DEEP (Digibind Efficacy Evaluation in Preeclampsia). A total of 51 women were
enrolled and 24 received drug for up to 48 hr. The primary outcome measures for the trial were a
greater creatinine clearance (a measure of renal function) and reduced use of anti-hypertensive
medications in women receiving drug. The first goal was achieved but the second was not. One
serious problem with the second goal was that 40% of the women enrolled were already on antihypertensive medications and typically such medications would not be discontinued even if
blood pressures improved. More information is provided about this particular study for two
reasons: Our laboratory provided most of the laboratory experiments that were part of the study
and the results of those experiments represent the basis for the research described in this
chapter12.

As mentioned, our laboratory determined the serum levels of EDLFs present in the serum of
the severe PE women enrolled in the DEEP trial. The determinations were made using the
amount of Rb+ taken up into human red blood cells over a 45 min period in the presence of
serum from non-pregnant individuals, uncomplicated pregnant women and the individual serum
from the subjects in the trial. Rb+ is taken into the cells by the sodium pump, SP or
(Na+,K+)ATPase, a protein complex that moves 3 sodium ions out of the cell and 2 potassium
ions in. Rubidium ion is handled like potassium. If there are inhibitors of the SP present, the
amount of rubidium taken up as a function of time is decreased. Also ouabain, a specific SP
inhibitor, at 10-3 M was used as a control to define 100% SP inhibition. Conceptually,
administration of Digibind with its ability to selectively bind EDLFs and block their activity,
should cause the SP activity to increase (and the SP inhibition to be relieved), if EDLFs are
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present. Likewise, aspects of the disease mediated by EDLFs may also demonstrate
improvement.

Indeed, that was observed in the DEEP study. Levels of EDLFs were significantly reduced
and SP activity was significantly increased in PE women receiving Digibind compared with PE
women receiving placebo (Figure 10). Moreover, creatinine clearance (as a measure of renal
function) was significantly higher in PE women receiving Digibind compared with PE women
receiving placebo (Data not shown).

Figure 10. SP activity measured by Rb uptake into human red blood cells. Digibind reduced EDLF levels and
hence increased SP activity. 24 hr treatment of Digibind presented a better effect than 48 hr.
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As we have continued to analyze the data, we have found two results that suggest that
Digibind treatment is a more complex issue than previously thought.

In Fig 11, it is evident that Digibind treatment caused a very significant decrease in SP
inhibition in women receiving drug but it did not reverse entirely all of the EDLF produced
inhibition. Put another way it would appear that the Digibind dose regimen use in all DEEP
subjects was inadequate, at least for some portion of the subjects.

Figure 11. Digibind reversed SP inhibition produced by EDLF. The effect was not thorough but significant.

This leads to the second post hoc analysis that was done which was to determine the
distribution of EDLF in the subjects in the study. What was found was that ~20% of the subjects
had no measureable EDLF and that many had extremely high levels of EDLF (Figure 12). This
is not surprising given the heterogeneity of the disease itself.
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This has two implications: First, that Digibind treatment is likely to be ineffective in PE
women that are EDLF negative. Clearly, identifying these women would be highly useful to
prevent unnecessary and expensive therapy. Second, some women are likely to require a higher
dose of Digibind to complex all the EDLF and alleviate its effects. This most likely explains
why after treatment that there was not complete normalization of EDLF levels in the treated
severe PE women.

Figure 12. Distribution of EDLF in serum. ~20% of the subjects had no measurable EDLF.

This idea is borne out in part when looking at those severe PE women in the DEEP trial
who were EDLF positive. If one considers the data in this way, then one finds that as expected
the Digibind effect is more substantial in EDLF positive women and no effect is observed in the
EDLF negative women. See Fig 13.
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Figure 13. Digibind effects on PE women with positive or negative EDLF. EDLF positive women showed more
substantial Digibind effects than EDLF negative women.

Similar results were observed for the creatinine clearances in these women. Specifically,
the creatinine clearances were only higher in the Digibind treated EDLF positive women and the
Digibind effect was even more pronounced and significant when the EDLF negative subjects
were excluded (Data not shown).

Because the DEEP trial experiments suggested that not all preeclamptic women appeared
to have appreciable levels of EDLF present in their circulation, the need to identify women likely
to respond to therapy and a means to choose an appropriate therapeutic dose became obvious.
Consequently, a method to identify women having increased EDLF levels in serum and hence
likely to respond to therapy would be of significant value. Because Digibind recognizes and
binds the active EDLF in PE, we developed a radioimmunoassay (RIA) using Digibind as the
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primary antibody and tritiated ouabain as the tracer. Non-radiolabeled ouabain solutions with
graded concentrations were used as standards. The assay then measures the same EDLFs
endogenous to PE women which it would bind and inactivate as part of Digibind therapy. Hence,
this assay serves as a probe to identify women having observable serum EDLF and which
consequently should respond to Digibind treatment, i.e. a theranostic test.

In addition, there appeared to be correlation between this radioimmunoassay employing
Digibind and the rubidium uptake Graphite Furnance Atomic Absorption Spectrometry (GFAA)
bio assay, which measures inhibition of Rb+ uptake in human red blood cells. It suggested that
this Digibind RIA is a reliable approach to detect EDLF concentrations.

Because Digibind is discontinued and problematically expensive to use as part of a
common immunoassay, we sought to identify a comparable monoclonal antibody (Mab) raised
against digoxin as the immunogen to replace Digibind. We have screened over 10 different
mouse Mabs from different companies with different dilutions and found a few that demonstrate
an interaction with the EDLF.

Methods
Placental conditioned medium culture
Placentas were obtained immediately after delivery and 4-5 small tissue pieces (~5mm x
5mm x 5mm) were cut off from the inner section. The tissue pieces were dissected into tiny
granules with sterilized scissors. Any visible clots and blood vessels were removed with
sterilized tweezers. The remaining villi were washed repeatedly with PBS to remove blood from
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the intervillous space. Villous tissue of ~5 mg/well was then patted dry by sterilized paper tower
and incubated in a 6-well cell culture plate with 5 mL of serum free DMEM (Gibson, Grand
Island, NY, USA) containing 100 U/mL penicillin, 100 g/mL streptomycin and 0.25 g/mL
amphotericin B (Sigma, St. Louis, MO, USA) for 48 hours (a general tissue incubation time of
placental conditioned media13) at 37˚C in an incubator gassed with 95% air and 5% CO2.

At the end of incubation, samples of the culture medium were collected in 15 ml conical
tubes and any residual villi were removed by centrifuging at 4000 rpm for 2 min. The
supernatant was stored at -80˚C as conditioned medium until later processing and assay.

Digibind Radioimmunoassay (RIA)
Sera or conditioned media samples were collected and assayed by radioimmunoassay.
Digibind (GlaxoSmithKline, Research Triangle Park, NC, USA) was used as the primary
antibody interacting with either EDLF or ouabain and rabbit anti-sheep immunoglobulin (IgG)
Fab fragment (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) was used as
the secondary antibody. Digibind represents the Fab fragments of an anti-digoxin antisera
produced in sheep and used therapeutically to counteract digoxin overdose in humans. Tritiated
ouabain (30.0 Ci/mmol, Perkin Elmer, Boston, MA, USA) acted as a tracer. Cold ouabain
solutions at graded concentrations were used as standards. A 100 L aliquot of specimen or
standard ouabain solution (50 nM, 0.1 M, 0.2 M, 0.5 M, 1 M, 3 M), 50 L of a 2.22 x 10-8
M tritiated ouabain solution, 300 L of 1.8 g/mL Digibind solution, 60 L of 2.12 x 10-7 M 2˚
Ab solution and 10 L of 10 mM pH 7.4 Tris buffer were combined and mixed well, then
incubated at room temperature overnight to allow antigen-antibody binding. In conditioned
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media assays, because samples contained DMEM medium, 100L of DMEM were added to
standard reaction solutions and 100L of deionized H2O were added to specimen reaction
solutions to bring them to the same final volume and composition. EDLF in the several
conditioned media/homogenate specimens or standard cold ouabain in the calibrating solutions
competed with the labeled ouabain for Digibind and then the 2˚ antibody was added to bind to
the primary (1˚) antibody-antigen complex and decrease its solubility.

After the overnight incubation ( We also tried shorter time incubation such as 2 hrs, 4 hrs
and 8 hrs but did not get satisfactory data, so finally chose overnight as the optimal incubation
time), 563 L of 16% polyethylene glycol (PEG)-6000 (Calbiochem, La Jolla, CA, USA) was
added to each reaction solution to precipitate the antibody-antigen complex. After centrifugation
at 13,200 rpm for 30 min, the supernatant was discarded and the pellet was resuspended in 500
L of 0.05 M phosphate buffer (pH 7.0). Then 4 mL of EcoscintTM, a scintillation fluid (National
Diagnostics, Atlanta, GA, USA) was added to the resuspended solution, and radioactivity in the
mixture was measured by scintillation counter to determine EDLF concentration. All individual
specimens were assayed in duplicate.

Rubidium (Rb) Uptake Graphite Furnance Atomic Absorption Spectrometry (GFAA)
Conditioned media with EDLF released from cultured placental tissues were assayed by
Digibind RIA as previously described to determine EDLF concentration. Simultaneously the
samples were assayed by Rb+ uptake using a graphite furnace atomic absorption instrument
(GFAA, model 4100Z, Perkin Elmer, Waltham, MA, USA) that measures [Na+,K+]ATPase–
dependent Rb+ transport activity into fresh human red blood cells (RBCs). Ouabain at 10-3 M
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was used in this assay as a control to achieve complete inhibition of the [Na+,K+]ATPase ion
transport activity.

Blood was collected from non-pregnant healthy volunteers into EDTA containing tubes,
left to stand at room temperature for one hour and centrifuged at 4000 rpm at 4˚C for 10 min to
remove the cells from the plasma. The remaining RBCs were washed with two volumes (10 mL)
of RbCl buffer (containing NaCl 135 mmol/L, RbCl 6.73 mmol/L, NaH2PO4 8.10 mmol/L,
Na2HPO4 1.27 mmol/L and MgCl2 1.0 mmol/L, pH 7.45, but omitting K+) three times vortexing
for 5 min before recollecting the cells by centrifuging at 4000 rpm at 4˚C for 10 min.

After washing and the 10% hematocrit solution prepared, 800 L of RBC, 100 L of
conditioned media sample or control (ouabain at 1.00 x 10-3 M final concentration) and 100 L
of Digibind solution (1.00 x 10-6 M final concentration) were mixed in an Eppendorf tube and
rocked in an incubator at 37˚C at 220 rpm for 45 min to allow Rb+ ion uptake into the cells.
After incubation, each bioassay solution was centrifuged at 4000 rpm for 10 min to isolate the
RBCs from the RbCl buffer. The RBCs were then washed by adding 1 ml of ice cold washing
buffer (containing choline chloride 149 mmol/L, MgCl2 1.0 mmol/L, MOPS 5.88 mmol/L, Tris
2.12 mmol/L, pH 7.40) and centrifuged again to remove any residual extracellular Rb+. This
washing process was repeated 3 times.

Cells were lysed by addition of deionized H2O, centrifuged to remove cell ghosts and
stored at -80˚C overnight. Rb+ uptake into the cells was then measured by standard operation of
a GFAA instrument equipped with a rubidium lamp to determine EDLF ability to inhibit
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[Na+,K+]ATPase mediated ion transport. Before the GFAA step, 10 L of the isolated RBCs
were diluted to 500 L with deionized H2O of which the autosampler of the GFAA injected
10L for Rb+ ion quantitation. All samples were tested in triplicate.

Monoclonal (Mab) Radioimmunoassays
This assay was carried out to screen Mabs from different companies at different dilutions.
At this stage of development only cold ouabain standards were used, and sera or conditioned
media specimens were not tested. Monoclonal mouse antibody anti-digoxin (Mab) listed below
was used as the primary antibody anti-EDLF/ouabain and rabbit anti-mouse immunoglobulin
(IgG) whole molecule (Sigma, St. Louis, MO, USA) was used as the secondary antibody.
Tritiated ouabain (30.0 Ci/mmol, Perkin Elmer, Boston, MA, USA) acted as a tracer. Cold
ouabain solutions at graded concentrations were used as standards. A 100 L aliquot of one of
the standard ouabain solutions (50 nM, 0.1 M, 0.2 M, 0.5 M, 1 M, 3 M), 50 L of a 2.22 x
10-8 M tritiated ouabain solution, Mab solution (amounts, concentrations and dilutions listed
below), 60 L of 1.8-2.5 mg/mL (original concentration provided by Sigma) 2˚ Ab (typically
1:50 dilution, exceptions listed below) and 10 L of 10 mM pH 7.4 Tris buffer were combined
and mixed well, then incubated at room temperature overnight to allow antigen-antibody binding.
EDLF in the standard cold ouabain competed with the labeled ouabain for the Mab and then the
2˚ antibody was added to bind to the 1˚ antibody-antigen complex and decrease its solubility.

After the overnight incubation, 563 L of 16% polyethylene glycol (PEG)-6000
(Calbiochem, La Jolla, CA, USA) was added to each reaction solution to precipitate the
antibody-antigen complex. After centrifugation at 13,200 rpm for 30 min, the supernatant was
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discarded and the pellet was resuspended in 500 L of 0.05 M phosphate buffer (pH 7.0). Then 4
mL of EcoscintTM, a scintillation fluid (National Diagnostics, Atlanta, GA, USA) was added to
the resuspended solution, and radioactivity in the mixture was measured by scintillation counter
to determine EDLF concentration. All individual specimens were assayed in duplicate.

Mabs we screened:
300L of Mab from OEM concepts (Saco, ME, USA) with original concentration 3.5
mg/mL was tested at 1:500 dilution.

150 L of Mab from MyBioSource (San Diego, CA, USA) with original concentration
5.78 mg/mL was tested at 1:300, 1:400, 1:500, 1:600 and 1:800 dilutions, and the 2˚ Ab was
applied at 1:40, 1:50, 1:60, 1:75 and 1:100 dilutions respectively

200 L of Mab from Genway (San Diego, CA, USA) with original concentration 1
mg/mL was tested at 1:100 and 1:200 dilutions, and the 2˚ Ab was applied at 1:50 and 1:100
dilutions respectively.

300 L of Mab from Abcam (Cambridge, MA, USA) with original concentration 0.6
mg/mL was tested at 1:100 dilution.

200 L of Mab from AbD seroTec (Raleigh, NC, USA) with original concentration 1
mg/mL was tested at 1:100 and 1:200 dilutions, and the 2˚ Ab was applied at 1:50 and 1:100
dilutions respectively.
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150 L of Mab from Biodesign (Saco, ME, USA) with original concentration 5.78 mg/mL
was tested at 1:300, 1:400 and 1:500 dilutions, and the 2˚ Ab was applied at 1:40, 1:50 and 1:60
dilutions respectively.

200 L of Mab from Santa Cruz (Santa Cruz, CA, USA) with original concentration 100
g/ mL was tested at 1:10 dilution.

300 L of Mab from Lifespan (Seattle, WA, USA) with original concentration 2.89
mg/mL was tested at 1:400 and 1:500 dilutions, and the 2˚ Ab was applied at 1:50 and 1:60
dilutions respectively.

200 L of Mab from ARP (Belmont, MA, USA) with original concentration 1 mg/mL
was tested at 1:100 dilution.

150 L of Mab from Thermo Scientific (Rockford, IL, USA) with original concentration
5.78 mg/mL was tested at 1:400 dilution.

300 L of Mab from Sigma (St. Louis, MO, USA) was tested at 1:100, 1:300, 1:500,
1:800, 1;1000, 1:2000 and 1;5000 dilutions according to the datasheet suggestion (1:10000 for
ELISA), and the 2˚ Ab was applied at 1:40, 1:50, 1:60 and 1:100 dilutions for each primary Ab
dilution.
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300 L Mab from Fitzgerald (Concord, MA, USA) with original concentration 3.45
mg/mL was tested at 1:250, 1:500 and 1:1000 dilutions, and the 2˚ Ab was applied at 1:30, 1:50
and 1:100 dilutions respectively.

Statistical Analyses
Results are reported as the mean + 1 SEM. Comparisons of the EDLF RIA with the GFAA
Rb+ ion uptake assay were carried out by Pearson‟s Product Moment Correlation analysis.
Effects of time or concentration on EDLF release from placental tissue were analyzed by
ANOVA with post hoc Dunnett‟s pair-wise comparisons. A p-value of <0.05 was considered
significant.

Results
Using Digibind as the primary antibody, rabbit anti-sheep immunoglobulin (IgG) Fab
fragment as the secondary antibody, tritiated ouabain as tracer, and cold unlabeled ouabain
solutions at graded concentrations as standards, a standard curve of Digibind radioimmunoassay
was developed for each assay (a typical standard curve is shown in Figure 14). EDLF
concentrations were calculated by reference to the ouabain standards and reported as ouabain
equivalent concentrations.
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Figure 14. Standard curve for the Digibind RIA. Increasing ouabain concentration (shown as the – log [ouabain])
caused a progressive displacement of [3H]-ouabain from the Digibind and a reduction in counts of radioactivity.
The y-axis displays counts of radioactivity measured after the fixed incubation time as a function of ouabain
concentration shown on the x-axis

Using the above standard plot, EDLF has been measured by Digibind RIA in the serum of
pregnant women with PE (Figure 15). Some women have substantially higher concentrations of
EDLF, e.g. serum 2 and 5, than others.
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Figure 15. RIA of PE sera. Serum from seven women with PE was assayed using the Digibind RIA. All showed
easily detectable levels. Note that some women have substantially higher concentrations of EDLF, e.g. serum 2 and
5, than others.

In addition, this assay was also successfully applied to measure EDLFs secreted in the
culture media of freshly explanted human placenta. 11 conditioned media specimens assayed by
both Digibind RIA and by SP inhibition Rb uptake using a red blood cell assay demonstrated that
there was a significant correlation between these two assays (Figure 16, n=11, p=0.019). The
data provided evidence to demonstrate the reliability and comparability of this
radioimmunoassay employing Digibind for EDLF and the Rb+ uptake assay.
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Figure 16. Conditioned media taken from normal human placentas was assayed for EDLF by RIA (y axis) and also
for its ability to inhibit the SP in human red cells (x-axis). There was good correlation between the two assays for
the several cultured media assayed (n=11, R=0.69, p=0.019).

In an effort to find a monoclonal antibody replacement of Digibind, we screened over 10
Mabs from different companies. Initially we determined the dilution of each Mab according to
its original concentration or the manufacturer‟s datasheet suggestion to make the final
concentration close to the concentration of Digibind employed in this RIA. Then additional
dilutions were applied if the results showed any promise, i.e. cold ouabain displaced more that
20% of the labeled tracer. Likewise, the concentration of the secondary Ab was also altered if
needed. In order to screen more Mabs in a short period, at the beginning of each screen we only
used three concentrations of cold ouabain standards instead of the entire set of standards with all
graded concentrations, and used a more complete set of ouabain concentrations if the results
were promising.
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Of all the monoclonal anti-EDLF we screened for replacing Digibind, Figure 17 shows a
typical poor performance of a Mab in an RIA assay, which is characterized by very low counts of
the radioactivitybeing bound (<500 cpm) or very little change with increasing standard. The low
radio-count indicates that the binding between the Mab and ouabain is quite low or even no
immuno-binding. Therefore, after the precipitation step, most of free tritiated ouabain was
unbound and discarded and the residue tritiated ouabain showed low radio-counts.
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Figure 17. Standard Curve for the monoclonal antibody RIA from ARP. Only three ouabain concentrations (shown
as the – log [ouabain]) were tested. The y-axis displays counts of radioactivity measured after the fixed incubation
time as a function of ouabain concentration shown on the x-axis.
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However, a few Mabs showed higher counts being bound but the trend of the plot was only
useful at high (> 10-7 M) ouabain concentrations making unlikely that such an assay would
measure the relatively low levels of EDLF found in pregnant serum. Figure 18 is a sample of the
standard curve from Therm Inc., which is another typical result of the Mabs we screened. With
higher cold ouabain concentrations, more 3H ouabain was displaced resulting in a useful change
in counts after the precipitation and centrifuge steps, and hence adequate to measure high EDLF.
As shown in this figure, we could not see this trend clearly at low ouabain concentration. It
means that the binding between ouabain and the Mab might not be strong or stable enough to
accomplish the assay comparable to Digibind.
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Figure 18. Standard Curve for the monoclonal antibody RIA from Therm. Increasing ouabain concentration (shown
as the – log [ouabain]) caused a trendless displacement of [3H]-ouabain from the Mab. The y-axis displays counts of
radioactivity measured after the fixed incubation time as a function of ouabain concentration shown on the x-axis.
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Nevertheless, Figure 19 shows a sample standard curve of a Mab superior to the others
which could be considered for a theranostic. The Mab was from Fitzgerald Industries. Compared
with Figure 14, this Mab under the particular assay conditions employed here did not perform as
well as Digibind. The trend of the plot is relatively clear compared with other Mabs, but the
counts of the radioactivity were not as high as found typically with Digibind, especially the
starting point representing the absence of cold ouabain but presence of tritiated ouabain in the
reaction mixture, which should show very high radioactivity bound. Improvements in the
performance may be achievable with a more extensive optimization of antibody concentration,
tracer concentration, etc. However, the intent was to determine the feasibility of a Mab
replacement for Digibind and that has been accomplished. Further attempts to identify a better
Mab can be carried out as more become commercially available.
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Figure 19. Standard Curve for the monoclonal antibody RIA from Fitzgerald. Increasing ouabain concentration
(shown as the – log [ouabain]) caused a progressive displacement of [3H]-ouabain from the Mab. The y-axis
displays counts of radioactivity measured after the fixed incubation time as a function of ouabain concentration
shown on the x-axis.

Discussion
These studies demonstrate that a theranostic using Digibind was achieved. It appeared able
to identify women with varying amounts of serum EDLF. Results using this assay appeared to
identify the biologically active SP inhibitor responsible for some abnormalities found in PE as
confirmed by Rb+ uptake assay. This assay provided much more reproducible results compared
with the Rb+ uptake assay (data not shown) and was much easier and simpler to perform. It
required only instrumentation that is often found in clinical or hospital laboratories unlike GFAA
instruments which are uncommon even at research institutions. Replacement of Digibind with a
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digoxin Mab is possible and RIA assays have shown initial promise using existing anti-digoxin
Mabs. Using the Fitzgerald Mab may be sufficient to develop a clinically useful RIA. This would
require some improvements in assay performance but such optimization is more a commercial
undertaking rather than a basic science question.

Additional Mabs can be screened, as they become available, to identify any with greater
promise than the Fitzgerald Mab in developing an RIA theranostic. Once the RIA has been
developed, it should be possible to adapt the RIA to an ELISA format or a multiplex analyzer
format and eliminate the use of radioactive tracer. However, such work is beyond the scope of
this project and again reducing the assay to routine practice is now appropriate for companies
that specialize in such commercialization practices.
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Chapter 4: Tissue Source and Isolation of EDLF

Introduction
Although there have been many clinical studies indicating that EDLF is involved in
essential hypertension and experimental hypertension1, the chemical identity of the factor or
factors present in blood producing the SP inhibition or vasoconstriction, has not been established.
Indeed, there have been several compounds isolated from blood, tentatively identified and
proposed as the circulating ELDF. All of them are structurally like the steroid glycoside
digoxin2, 3 (Figure 4 in Chapter 1).

Despite the compelling clinical data and experimental animal hypertension data,
controversy has surrounded the identity and perhaps even the existence of EDLFs4, 5. There have
been those who have proposed that these compounds isolated from mammalian sources and
touted as EDLF are actually part of the food chain, externally obtained and not produced by the
body. For example, ouabain has been proposed as the major EDLF but it contains a rhamnose
group attached to the sterol 3-O site and rhamnose has no known synthetic pathway in mammals
and is not found as part of native molecules in mammals. Consequently, having clear,
unambiguous evidence for tissue synthesis of one or more EDLFs would represent a major
milestone in this field.

Moreover, knowing the exact structure of the ELDFs that participates in PE would be very
helpful in clarifying EDLF‟s role in this particular disease and its potential role in one or more of
the several actual disease processes that occur in PE. Also, such knowledge would allow for the
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development of more accurate measurements of circulating levels of the EDLF or EDLFs that
mediate disease in PE women. It would also quite possibly allow for antagonists of EDLF to be
developed and used in future therapeutic treatment of women with PE. In the past, the primary
obstacle to study EDLF was its low quantities in serum. Consequently, an additional major and
unmet need in this field is to identify an easily obtained and maintained tissue source that
contains and/or produces useful quantities of one or more EDLFs for use in the laboratory. In
order to identify and characterize EDLF in PE, a predictable and enriched source of the factor
would seem to be a prerequisite.

Clinical trials revealed that abnormalities of PE, such as hypertension and proteinuria, are
reversed when the placenta was delivered6. Therefore, we hypothesized that placenta might be a
source of EDLF. To test our hypothesis, we developed a method to prepare a consistent
homogenate using a ball mill homogenizer and frozen placentas and then deplete intrinsic
proteins from homogenates to simplify and purify the specimen and avoid interferences in
further assays. EDLF levels in the homogenate specimens were measured by Digibind RIA as
described in Chapter 3. Both normal and preeclamptic placentas were assayed and compared.

Furthermore, because progesterone is produced in substantial quantities by the placental, an
evaluation of the effect of progesterone on Digibind was designed to determine the
crossreactivity of the Fab for progesterone. This was important to insure that the Digibind is
specific to and measures only EDLF and hence is an appropriate assay for further studies of
EDLF synthesis and regulation.
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More importantly we have designed and tested an ultrafiltration method using Digibind as
an immuno-affinity agent that can bind the EDLF and extract it. This approach exploits the
strong binding between Digibind and EDLF, as well as takes advantage of their distinct
molecular weights. Digibind has a known molecular weight of close to 50,000 Daltons, whereas
EDLFs‟ molecular weights are estimated to be around 400-700 daltons. Hence, a specific
ultrafiltration membrane with a 30,000 Dalton cut off was considered for use to isolate first free
EDLF from large molecular impurities, second the EDLF-Digibind complex from small
molecular weight impurities, and finally free EDLF from Digibind. This allowed Digibind to
remove EDLF specifically from most of the other materials present in the protein-depleted
placental homogenates. Finally the EDLF isolated from placental homogenates or from
conditioned media exposed to placenta was examined by Digibind RIA.

Methods
Placental homogenate preparation
Placentas were obtained from both normal pregnancies and preeclamptic pregnancies
immediately after delivery and a full thickness cut (~2cm x 2cm x 2cm) was removed, snap
frozen in liquid nitrogen and stored at -80˚C until later processing and assay. Placental pieces
were shaved into flakes using a surgical blade and tissue flakes were placed into a Sartorius
Mikro Dismembrator stainless steel cylinder along with 15 stainless steel balls. The entire
cylinder, including contents, was submerged in liquid nitrogen for 4-5 minutes. After the
thorough freezing of the cylinder contents, the cylinder was placed in a Sartorius ball mill
(Sartorius, Bohemia, NY, USA) and shaken at 2000 rpm for 10 minutes. The process of
submersion and shaking was repeated until the contents became a fine powder.
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The placental homogenate was transferred from the cylinder to a 50 mL conical tube and
the volume was brought up to 5 mL by adding deionized H2O. To remove protein, two volumes
of methanol (10 mL) were added gradually to the homogenate while the mixture was vortexed
continuously for 5 minutes. The placental sample mixture was then centrifuged for 10 min at
4000 rpm to remove the precipitated proteins.

The supernatant was transferred to a new conical tube and dried down overnight in vacuo
to remove residual methanol. Then the volume was brought back to the original volume of 5 mL
using deionized H2O. The placental homogenate was store at -80˚C for further processing and
assay.

Placental conditioned medium culture
As previously described in Chapter 3, placentas were obtained immediately after delivery
and 4-5 small tissue pieces (~5mm x 5mm x 5mm) were cut off from the inner fetal side and
outer maternal side. The tissue pieces were dissected finely with sterilized scissors. After
removing clots and blood vessels, the villi were washed repeatedly with phosphate-buffered
saline (PBS) to remove blood. Fetal and maternal tissues of ~5 mg/well were patted dry by
sterilized paper tower and incubated in a 6-well cell culture plate with 5 mL of serum free
DMEM (Gibson, Grand Island, NY, USA) containing 100 U/mL penicillin, 100 g/mL
streptomycin and 0.25 g/mL amphotericin B (Sigma, St. Louis, MO, USA) for up to 48 hours (a
general tissue incubation time of placental conditioned media13 in Chapter 3) at 37˚C in an incubator
gassed with 95% air and 5% CO2.
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During the course of the incubation, samples of the culture medium were collected in 15
ml conical tubes and any residual villi were removed by centrifuging at 4000 rpm for 2 min. The
supernatant was stored at -80˚C as conditioned medium until later processing and assay.

Radio immunoassays of cultured media used standards in the assay that contained the same
amount of media as was contained in the unknown conditioned media exposed to placental tissue.

Progesterone crossreactivity experiment
In order to determine if results of Digibind RIA determinations represent EDLF levels
and not the presence of steroid compounds that weakly crossreact, we tested the effect of
progesterone, the main placental sterol, on the assay. Graded concentrations of progesterone
(20L) at final concentrations of 1.00 x 10-9 M, 1.00 x 10-8 M and 1.00 x 10-7 M, 100L of
deionized H2O, 100 l of conditioned medium sample, 50 L of tritiated ouabain solution, 300
L of Digibind solution, 60 L of 2˚ Ab solution and 10 L of 10 mM pH 7.4 Tris buffer were
combined and mixed well. A reaction solution containing 20L of deionized H2O instead of
progesterone solution was used as the negative control. All reaction solutions were incubated,
precipitated and analyzed as described in Digibind RIA procedure.

EDLF isolation by ultrafiltration
After depleting proteins and drying off residual organic solvent from the placental
homogenate samples, the homogenate was passed through an ultrafiltration filter membrane
(Amicon® Ultra, Ultracel – 30K specifically designed by Millipore, Carrigtwohill, Co. Cork,
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Ireland) to allow only those molecular species smaller than 30k Daltons to pass through. These
filter devices hold 4 mL of homogenate each. The 4 mL of protein-depleted, placental
homogenate were added to the top of the filter and placed in a fixed-angle rotor and centrifuged
at 2000Xg for 10 minutes.

The filtrate (~ 4 mL) was then incubated with 100 µL of 1x10-2 M Digibind, an amount
sufficient to bind all EDLF present in the filtered, protein-depleted placental homogenate, for
one hour at 37ºC in a shaker incubator (Boekel Scientific Model 136400, Feasterville, PA) set to
a medium speed. After incubation, the EDLF-Digibind complex containing solution was passed
through a new ultrafitration filter (Ultracel – 30K) again. This time we only centrifuged the
EDLF-Digibind for 1 min or until the centrifuge reached full speed and then the centrifuge was
turned off. This allowed most of the smaller compounds to pass through the filter and prevented
the EDLF-Digibind complex in the retentate to avoid adsorption on the filtration membrane.
About 1-2 ml of retentate were then reserved and treated with 392 µL of 0.2 M glycine (Sigma,
St.Louis, MO) (pH 3.0) to release the bound EDLF from the Digibind.

The glycine treated placental homogenate was then passed through the 30K filter a final
time followed by centrifuging at 2000Xg for 2 min. With this final filtration step the Digibind
remained in the retentate or on the membrane and the EDLF in the filtrate was essentially
purified from other endogenous compounds.

The pH of the ending filtrate was then neutralized

by adding ~ 18 µL of 1 M Tris (Fisher Scientific, Fair Lawn, NJ, USA).
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Statistics
Data are presented as the mean + 1 standard error. Comparisons of two groups were
accomplished by Student‟s t test if the data were normally distributed or by Wilcoxon Rank Sum
Test if not normally distributed. A p-value of <0.05 was considered statistically significant.

Results
Efforts to study the chemical nature of EDLFs have been difficult due to a lack of a readily
available, high abundance source of these factors. Research in this area has also suffered from
the inability to unequivocally demonstrate that EDLFs are actually produced by human tissues
and are not present in the body because of their ingestion and accumulation from food. To this
end preliminary data suggesting the presence of one or more EDLFs in placenta led to the
hypothesis that this might be a source for EDLFs and might explain their apparent increased
presence in serum during pregnancy, especially preeclamptic pregnancies.

Placental homogenate specimens were prepared as described in Methods and assayed by
Digibind RIA as described in Chapter 3 to determine EDLF concentrations in homogenates.
Figure 20 indicates that protein-depleted placental homogenates from women with PE often
appeared to have much higher EDLF levels than found in PE sera (compare with Figure 15 in
Chapter 3).
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Figure 20. RIA of PE placenta. Protein depleted placental homogenate from five women with PE was assayed
using the Digibind RIA. All showed easily detectable levels. Homogenate 4 and 5 have substantially higher
placental concentrations of EDLF than other specimens. In general placental concentrations were much greater than
serum concentrations.
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Figure 15. RIA of PE sera. Serum from seven women with PE was assayed using the Digibind RIA. These results
show lower EDLF levels in PE sera than in PE placental homogenates (notice the different scales shown in Fig 20),
but having comparable levels to those secreted EDLF levels from normal placentas (Compare with Fig 21).

As was found with PE serum, some women have substantially higher placental
concentrations of EDLF than others, e.g. homogenate 4 and 5. In addition, with this assay, we
detected levels of the EDLF factor or factors secreted in the culture media of freshly explanted
normal human placenta (Figure 21). The concentrations of secreted EDLF in the media from
normal placental culture were in the range of those found in PE sera (Figure 15).
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Figure 21. RIA of EDLF produced by cultured normal human placenta and accumulated over 48 hr. Media used to
culture fresh human placenta was protein depleted and assayed by RIA. All placentas elaborated EDLF from PE
women. In general media concentrations were in the range of those found in serum.

When more carefully examined, it was found that after 48 hr in culture, the fetal placental
membranes produced significantly higher levels of EDLF than did comparable amounts of
maternal placental tissue. See Figure 22 (n=5, fetal: 178 ± 14.9 vs n=5, maternal: 12.3 ± 6.3 nM
EDLF equiv, p=0.04). The EDLF was also shown to accumulate as a function of time in the
culture medium (Figure 23, n=5, 6hr: 87.6 ± 2.56, 12 hr: 237.0 ± 6.92, 24 hr: 393.2 ±14.76; 36 hr:
675.9 ± 26.89, 48 hr: 813.8 ± 18.77 nM ouabain equivalents EDLF; p<0.05) indicating EDLF
production. Based on these observations, and Figure 16 in Chapter 3, which showed that the
concentrations of the secreted factors detected by Digibind RIA appear to be the same as the
secreted placental circulating factors with the ability to inhibit the SP activity in red blood cells,
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we concluded that the factors secreted in the culture media were EDLF and placenta appeared to
be a source of EDLF.

Figure 22. Comparison of human placental maternal membrane and fetal membrane EDLF levels released after 48
hr culture. Concentrations of EDLF secreted from fetal side of placentas were significantly higher than maternal side
(n=5, p=0.04).
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Figure 23. EDLF accumulation in culture medium as a function of time. Longer incubation times produced
significantly more EDLF secreted into the medium (n=5, p<0.05).

Given that the placenta produces substantial quantities of steroid hormones, particularly
progesterone, it was important to insure that the factor(s) detected by the Digibind RIA was
EDLF and that the observed levels of EDLF did not represent progesterone. Experiments were
conducted to determine progesterone crossreactivity with the RIA. EDLF levels could not be
accounted for by progesterone being measured by the RIA. Even adding enough progesterone to
produce a final concentration of 1.2X10-7 M of progesterone, which is substantially higher than
reported levels of placental progesterone in the literature7, the concentrations of EDLFs secreted
into the media were not altered appreciably. Also, progesterone does not inhibit the RBC SP.

In addition, experiments were conducted to demonstrate that the concentration profile of
EDLFs measured on dilution showed the anticipated proportional effect unlike non-specific
interferents with RIAs which often have a somewhat constant negative interference with the
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assay at most concentrations. Digibind RIA data of EDLF concentrations in placental
homogenates from women with PE and those from women with uncomplicated pregnancies
showed that PE placentas had increased EDLF levels and this difference between normal and PE
homogenates were still significant even with sequential dilutions of the specimens (Figure 24,
n=8, ctl: 74.4 ± 4.1 vs n=8, PE: 329 ± 52 nM EDLF equiv, p=0.0002). These data further verified
that RIA employing Digibind as the antibody is a reliable approach to evaluate EDLF levels,
human placentas could be used as an enriched source of EDLF and the placental EDLF secreted
in the culture media could be analyzed for the study of EDLF synthesis and regulation.

Figure 24. Comparison of the EDLF concentration in protein free placental homogenates from women with
preeclampsia (n=8, PE) versus women with uncomplicated pregnancies (n=8, CTL) by radioimmunoassay.
Differences were statistically significant for undiluted homogenate (neat, p=0.0002) or with sequential dilutions (1:2
dilution p=0.002, 1:3 dilution p=0.002, 1:4 dilution p=0.02)

72

In order to further verify the presence of an EDLF in placental homogenates, EDLF
isolation from other components of placental homogenates was accomplished using an affinity
approach employing Digibind coupled with ultrafiltration. The assay was applied to measure free
EDLF levels (none containing Digibind) at different stages of the purification process: first in
the protein-depleted homogenate, then after its removal from the homogenate by the Digibind
and finally the EDLF after both release from the Digibind and after ultrafiltration (Figure 25).
The protein-depleted homogenate reconstituted in buffer (Tissue, left bar) showed substantial
amounts of ELDF measured by RIA. Then this protein-depleted homogenate was incubated with
Digibind. The EDLF, which is small, was bound by the Digibind, which is large. When the
mixture was ultrafiltered (UF) through a 30 kD ultrafilter, the EDLF was mostly retained by the
Digibind Fab with very little appearing in the ultrafiltrate (Filtrate, middle bar). RIA
measurement of EDLF showed significant (p<0.05, Wilcoxon Rank Sum Test, n=4) reductions
in EDLF levels after Digibind treatment and UF. Then glycine at pH 3 was used to release the
EDLF from Digibind and this solution was ultrafiltered. EDLF was found to be released and
then to pass through the UF membrane. The solution was then neutralized and assayed by RIA
for EDLF (Released, right bar) which demonstrated significantly more EDLF (p<0.05 Wilcoxon,
n=4) present than in EDLF depleted solution shown in the middle column, providing solid
evidence that EDLF was retained by Digibind and then released.
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Figure 25. Use of Digibind as an affinity material. Columns showed free EDLF concentrations measured by
Digibind RIA. Tissue, left bar: the protein-depleted homogenate; Filtrate, middle bar: homogenates incubated with
Digibind and then ultrafiltered through a 30 kD ultrafilter; RIA measurement of EDLF showed significant (p<0.05,
Wilcoxon Rank Sum Test, n=4) reductions in EDLF levels after Digibind treatment and UF; Released, right column:
pH 3 glycine treated solution followed by another ultrafiltration; RIA data demonstrated significantly more EDLF
(p<0.05 Wilcoxon, n=4) present than in the filtrate.

Discussion
One of the most fundamental limitations of research on EDLFs has been the lack of a
clear demonstration of its secretion from a mammalian tissue source. Critics have contested the
very existence of endogenous cardiac sterols in humans proposing that the SP inhibitory activity
observed in the serum of individuals with hypertension may arise from external sources. Indeed
ouabain administered to animals is actively taken up by the adrenal1, 8. Digoxin and digitoxin are
dispersed into lipophillic tissues and small amounts equilibrate slowly with the vascular
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compartment1, 8. Hence, plant-derived cardiac glycosides could be partitioned into animal tissue
albeit in very small amounts.

Our results collectively strongly support that human placenta produces and secretes one
or more EDLFs. This presents compelling evidence for a synthetic pathway being present in at
least one human tissue. This pattern of secretion was not uniform throughout the placenta, but
high levels were clearly shown to come from the fetal membranes. It is known that the
trophoblast cells of the placenta have the ability to synthesize sterol compounds9. However, this
EDLF secreted by the placenta cannot be explained by the high levels of progesterone produced
by the placenta. Experiments described in the next chapter extend these findings by exploring
regulation of EDLF systhesis.

The need for an enriched source of EDLF has been a long standing need in this field of
research. These results demonstrated compellingly that we have a reliable and enriched source
of the EDLF of PE --- placenta. Not only that but the evidence strongly suggests that human
placenta produces and releases substantial amounts of EDLF, quantities similar to those found in
the circulation of pregnant women. In addition, we have a sensitive and specific approach to
detect EDLF levels in placenta --- a radioimmunoassay employing Digibind as primary antibody.
Finally, we have developed ways of isolating EDLFs using Digibind as affinity agent and using a
selected ultrafiltration step to isolate EDLF from placental specimens or from conditioned media.
These results make the further study of EDLF structure, its synthesis and regulation promising.
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Chapter 5: EDLF Synthesis and Regulation in Placenta

Introduction
Having developed a specific immunoassay to measure EDLF concentrations and having
identified a promising tissue source of EDLF production, it was then possible to attempt to
provide a greater understanding of EDLF tissue synthesis and to identify factors that may
regulate that production. Such a demonstration of specific synthetic steps and regulated secretion
of EDLFs would represent a marked advance in this research. It would help to integrate EDLF
into the overall context of PE and other hypertensive diseases.

Current evidences all suggest that EDLF is a sterol having an unsaturated lactone ring
attached to the 17-C of the steroid backbone1, 2. Consequently, the hypothesis is that its
synthetic pathway should share steps with the steroid synthetic pathway. There are known
substrates of these enzymatic steps and also some agents that can block the enzymes involved in
the pathway. In this chapter, we applied these known agents to placental tissues in culture and
tried to elucidate mechanisms of EDLF synthesis and regulation using the Digibind
radioimmunoassay.

First of all, we needed to verify the hypothesis that synthetic pathway of EDLFs share
steps of the steroid synthetic pathway. It is known that ketoconazole is an agent that generally
blocks steroid synthesis by inhibiting several cytochrome P-450-dependent enzymes. These
kinds of enzymes are widely involved in steroidogenesis, such as cholesterol side-chain cleavage
enzyme, hydroxyl steroid dehydrogenase (HSD), 17-hydroxylase, 17-20 lyase and 11-

77

hydroxylase (shown in Chapter 1, Figure 3)3. Therefore, we hypothesized that ketoconazole
would inhibit EDLF synthesis. If the EDLF biosynthetic pathway shares steps with
steroidogenesis, ketoconazole should be an inhibitor of EDLF synthesis, and consequently,
addition of ketoconazole into placental tissue culture would decrease EDLF concentrations.

It was also hypothesized that if the EDLF synthetic pathway shared steps with
steroidogenesis one or more precursor compounds such as 17-hydroxyprogesterone could have
an effect on EDLF production in placental tissue culture. As shown in Fig 3 and Fig 4, 17hydroxyprogesterone is in the center of the steroidogenesis pathway and may contribute the
sterol backbone to EDLF structure. If its presence has an impact on EDLF production, it would
be consistent with its being an intermediate or substrate of EDLF synthesis. In order to further
clarify the role of 17-hydroxyprogesterone in the pathway, time course experiments were carried
out. Steady accumulation of placental EDLF with 17-hydroxyprogesterone treatment by time
would indicate that it is potentially a substrate of EDLF synthesis.

Besides EDLF synthesis, it is of considerable interest to understand more about EDLF
regulation. There are a several regulatory factors that are thought to be important in mediating
features of PE. Specifically, PE is thought to be a state of reduced oxygen perfusion leading to
increased oxidative stress with elevated levels of reactive oxygen species (ROS), including
hydrogen peroxide4. Also, it is thought to be a state of vascular endothelial damage with
increased levels of inflammatory cytokines5. One of the best documented of these in the setting
of PE is tumor necrosis factor α (TNFα). In this chapter, we hypothesized that there would be
effects of hypoxia, ROS, and cytokines on EDLF levels produced by placental tissue in culture.
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We also sought to determine if one of these pathways was responsible for the other, e.g. hypoxia
leading to increased cytokine production, to make clear if any or all of these factors contribute
directly to EDLF synthesis and release. Identifying the regulatory factors and elucidating the
mechanisms of their actions in PE would be very helpful to construct a more complete story of
EDLF synthesis and regulation, and hence provide deeper insights into the pathogenesis of PE
and subsequently develop earlier diagnosis and effective prevention of or therapeutic approaches
to PE.

It is believed that a decrease in oxygen to placenta tissue is a hallmark of PE. Placental
hypoxia resulting from reduced uteroplacental perfusion then leads to maternal endothelial
dysfunction, which in turn leads to later development of hypertension or impaired renal function,
important features in PE6, 7. Given that EDLFs can be causative factors of hypertension, knowing
the relationship between hypoxia and EDLF release would be helpful to understand the
pathogenesis of PE. In this Chapter we hypothesize that hypoxia is a condition that stimulates
greater EDLF levels in placenta. Hypoxia may induce endothelial dysfunction which stimulates
EDLF or perhaps it leads to increased EDLF which may contribute to endothelial dysfunction8.

There is increasing evidence supporting the possibility that oxidative stress is an important
contributor to the pathogenesis of PE. Compared with healthy pregnant women, preeclamptic
women have higher levels of ROS and lower levels of several dietary antioxidants in their blood,
including vitamin C and E, lycopene and betacarotene9. Elevated levels of markers of oxidative
stress, such as hydrogen peroxide, have also been observed in the placenta and circulation of
preeclamptic women. Overproduction of ROS destroys endothelium-derived nitric oxide in vitro
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and decreases its bioavailability, resulting in impaired endothelium-dependent vasodilatory
response and increased vascular resistance, which consequently could contribute to
hypertension10. Therefore, we hypothesized that oxidative stress could also regulate EDLF levels
in placenta.

Endothelial dysfunction, including altered levels of inflammatory cytokines, has been
thought to be a central pathophysiological feature in the maternal vascular system in PE11. Also,
increased circulating levels of cytokines, such as TNF and IL-6, have been found in
preeclamptic women12. Hence, PE could be considered as a state of exaggerated inflammatory
response. Convincing evidence suggested that inflammatory cytokines link placental hypoxia
with maternal endothelial, cardiovascular and renal dysfunction, all of which are abnormalities
that occur in PE11. Furthermore, our collaborator at Louisiana State University, Dr. Yuping
Wang, found that TNF-induced inflammatory response in endothelial cells could be reduced by
Digibind8. Consequently, we hypothesized that cytokines are regulatory factors of EDLF
production, that they induce an inflammatory response in PE by up-regulating EDLF release
from endothelial cells, and Digibind reverses this effect by binding with EDLF.

The results of the experiments presented here should be helpful in elucidating the
mechanisms and regulation of EDLF synthesis and should allow for more focused ideas and
studies on both the EDLF synthetic pathway and a possible therapeutic.
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Methods
Placental tissue culture with specified treatment
Placentas were obtained fresh shortly after delivery and processed as described in the
section “Placental conditioned media culture” in Chapter 3. Dissected placental tissues of 5 mg/
well were placed in a 6-well cell culture plate with serum free DMEM (Gibson, Grand Island,
NY, USA) of 5 mL/ well containing 100 U/mL penicillin, 100 g/mL streptomycin and 0.25
g/mL amphotericin B (Sigma, St. Louis, MO, USA). Before incubation, specified treatments
were carried out following the descriptions provided below respectively:

Effects of a general steroid synthesis inhibitor, ketoconazole, on placental EDLF production.
According to earlier published in vitro experimental data from other labs, which suggested
that 2-100 M of ketoconazole could reduce cholesterol synthesis, we chose 1 M, 2 M, 5 M,
10 M and 20 M as the concentrations of ketoconazole for these experiments13, 14, 15. The
graded concentrations of ketoconazole (Sigma, St. Louis, MO, USA) were added to the medium
which contain dissected placental tissues respectively and mixed well. Tissue culture without
ketoconazole was used as a control. In addition to 48 hr, the general placental tissue culture
incubation time, we also did 24 hr experiments to explore the effects of ketoconazole on EDLF
production with shorter time incubation. This was repeated 5 times.

Effects of a possible steroid synthesis precursor, 17-hydroxyprogesterone, on placental EDLF
production.
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Previous clinical research reported that human serum contains17-hydroxyprogesterone
(17-OHP) at levels around 2 nM, and that this level of 17OHP is 100- to 1000-fold too low to be
candidate for EDLF16, 17. Thus we carried out tissue culture experiments to assess the role of 17hydroxyprogesterone at concentrations of 200 nM, 500 nM, 1 M and 2 M on EDLF synthesis.
The graded concentrations of 17-hydroxyprogesterone (Sigma, St. Louis, MO, USA) were added
to the culture plate with medium as well as dissected placental tissues respectively and mixed
well. Tissue culture without 17-hydroxyprogesterone was used as a control. Because it has been
demonstrated that fetal placental tissues produce significantly higher EDLF levels than maternal
tissues, or maybe only fetal tissues produce EDLF. This is based on earlier studies reported in
Chapter 4, Figure 22 and on the results of ketoconazole experiments reported later in this
Chapter which showed that maternal tissues produced too little EDLF to affect the integrated
EDLF from the entire placenta (details in the following “Results” section). Consequently, we
used whole placenta cuts instead of attempting to separate the two sides for all following
experiments. 48 hr incubations were carried out. This was repeated 6 times.

Because our earlier data have shown that EDLFs were accumulated as a function of time
in placental tissue culture (Figure 23 in Chapter 4), we were interested if there were similar or
enhanced accumulation of EDLF production with the treatment of 17-hydroxyprogesterone as a
function of time. Hence, time course experiments (6 hr, 12 hr, 24 hr, 36 hr and 48 hr) were then
performed 5 times to study the effect of the potential substrate.

Effects of hypoxia on placental EDLF production
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In order to clarify if hypoxia could affect EDLF levels in placenta, we placed the culture
plates with dissected placental tissues in a portable air chamber (Billups-Rothernberg, Del Mar,
CA, USA) flushed daily with a gas containing 2% oxygen, 5% carbon dioxide, 93% nitrogen
(Airgas AcuGravTM, Salt Lake City, UT, USA) following hypoxic experiment conditions
reported by our collaborator of LSU18. The chamber was also housed in a regular incubator
gassed with 95% air and 5% CO2 to maintain 37˚C for 48 hr. Culture plate with similar media
and tissues placed directly in the regular incubator was used as a control. Also, we did 24 hr
incubations. This was repeated 6 times.

Effects of reactive oxygen species on placental EDLF production
We chose a known and also commercially available ROS, hydrogen peroxide, to elucidate
the effects of ROS on placental EDLF production. Given that high concentrations of hydrogen
peroxide are damaging to tissues, we started these experiments with hydrogen peroxide
concentrations of 1 nM, 5 nM, 10 nM and 20 nM. The graded concentrations of H2O2 (Fisher
Scientific, Fair Lawn, NJ, USA) were added to the culture plate with medium as well as
dissected placental tissues respectively and mixed well. Tissue culture without H2O2 was used as
a control. Both 24 hr and 48 hr incubations were performed. At each time the experiments were
performed 5 times.

Effects of cytokines on placental EDLF synthesis and release
TNF, a cytokine often involved in inflammatory processes including PE, was used to
verify our hypothesis that cytokines are agents capable of up-regulating EDLF release. Due to
the finding that high TNF levels causes tissue damage, we chose very low concentrations such
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as 1 nM, 2 nM, 5 nM, 10 nM and 20 nM to carry out these experiments. The graded
concentrations of TNF
with medium as well as dissected placental tissues respectively and mixed well and incubated for
48 hr. Tissue culture without TNF was used as a control. The experiments were carried out 6
times.

After incubation at 37˚C in an incubator gassed with 95% air and 5% CO2 (except the
hypoxic experiments), aliquots of the conditioned culture medium (~4-5 mL) were collected in
15 ml conical tubes and any residual villi were removed by centrifuging at 4000 rpm for 2 min.
The supernatant was stored at -80˚C as conditioned medium until later Digibind
radioimmunoassay.

Lipid hydroperoxide and TNF determination assay
After identifying some agents that modify the rate of EDLF synthesis in and release from
placenta, we were also interested in answering additional questions regarding such regulation.
More specifically, does hypoxia induce increased oxidative stress? Does hypoxia / oxidative
stress alter cytokine levels in placenta? In order to answer these questions, we used
commercially available kits to assay TNF and lipid hydroperoxide, a product of ROS mediated
free radical reactions and clear evidence of oxidative stress19. Answers to these questions should
allow a clearer picture of which processes are primary and which secondary to help understand
more precisely what may be directly responsible for changes observed.
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Conditioned media cultured with hydrogen peroxide or under low O2 conditions as well as
controls were collected and assayed by Lipid Hydroperoxide (LPO) Assay Kit (Cayman
Chemical, Ann Arbor, MI, USA) and Human TNF-alpha Quantikine ELISA Kit (R&D Systems,
Mineapolis, MN, USA). Data were analyzed following the instructions provide by the companies.
The experiments and assays were done 5 or 6 times, up to the amounts of conditioned media
collected from specified treatment described above.

Statistical Analyses
Results were reported as the mean + 1 SEM. Comparisons of just two conditions were
made by student‟s t-test if the data were normally distributed or by Wilcoxon Rank Sum Test if
they were not. Effects of time or concentration on EDLF release from placental tissue were
analyzed by ANOVA with post hoc Dunnett‟s pair-wise comparisons. A p-value of <0.05 was
considered statistically significant.

Results
Effects of a general steroid synthesis inhibitor, ketoconazole, on placental EDLF production.
To test the effects of the steroid synthesis inhibitor, ketoconazole, after freshly delivered
placenta was dissected and placed in incubation, we added graded concentrations of
ketoconazole into the culture medium of individual cultured placental tissues. Samples of
conditioned media were collected as a function of ketoconazole concentration and EDLF levels
were measured by RIA after 24 hr and 48 hr incubation respectively. Data showed that
ketoconazole caused inhibition of EDLF production and release into the culture media in a dose
dependent manner. Reductions were suggested by 24 hr but were more pronounced after 48 hr
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of exposure. In more detailed studies involving dissection of fresh placenta into maternal and
fetal tissues, a more elaborate different set of profiles was obtained. In the fetal tissues there was
a marked decrease in EDLF production in response to ketoconazole (Figure 26, n=5, 48 hr
control no ketoconazole: 178 ± 14.8 nM EDLF equiv compared with the progressive effects of
graded increasing concentrations of ketoconazole respectively, 48 hr 1 M ketoconazole: 79.9 ±
13.21, 48 hr 2 M ketoconazole: 55.8 ± 8.91, 48 hr 5 M ketoconazole: 16.0 ± 1.62, 48 hr 10
M ketoconazole: 14.7 ± 1.64, 48 hr 20 M ketoconazole: 12.5 ± 6.4 nM EDLF equiv; p=0.04)
whereas the maternal tissues showed little change or a possible small increase in EDLF
production compared with untreated tissue after 48 hr of ketoconazole treatment (Figures 27, n=5,
48 hr control no ketoconazole: 12.3 ± 6.3 nM EDLF equiv compared with the progressive effects
of graded increasing concentrations of ketoconazole respectively, 48 hr 1 M ketoconazole: 19.0
± 2.05, 48 hr 2 M ketoconazole: 17.9 ± 1.96, 48 hr 5 M ketoconazole: 18.3 ± 2.03, 48 hr 10
M ketoconazole: 17.3 ± 1.82, 48 hr 20 M ketoconazole: 24.6 ± 2.60 nM EDLF equiv; p<0.05).
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Figure 26. Concentration effect of ketoconazole on human plancental fetal side production of EDLF. Freshly
collected human placenta was dissected into fetal and maternal tissues. These were incubated in buffered culture
media for 48 hr in the absence or presence of graded concentrations of ketoconazole. The culture media was
collected and the amount of EDLF released from the tissue was measured using an RIA. The data show a significant
and progressive decrease in EDLF production with higher ketoconazole concentration (n=5, p=0.04, Wilcoxon Rank
Sum Test). EDLF release was significantly suppressed by 5, 10 and 20 M ketoconazole compared with no
ketoconazole as assessed by post hoc pair wisc comparisions (*, p<0.05).
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Figure 27. Concentration effect of ketoconazole on human plancental maternal side production of EDLF. Freshly
collected human placenta was dissected into fetal and maternal tissues. These were incubated in buffered culture
media for 48 hr in the absence or presence of graded concentrations of ketoconazole. The culture media was
collected and the amount of EDLF released from the tissue was measured using an RIA. The data show little change
with a small increase in EDLF released in response to ketoconazole (n=5, p<0.05, Wilcoxon Rank Sum Test, „0‟ vs
20 uM ketoconazole).

As shown in Figure 28, placenta has both fetal membranes and maternal membranes. The
results suggested a very robust and obvious effect of ketoconazole on fetal tissue EDLF
production. The results for maternal EDLF production are ambiguous, i.e. EDLF release was
very low initially and if anything seemed to increase slightly with increasing ketoconazole. This
may simply reflect that there was very little or no basal EDLF production and hence
ketoconazole would not have an effect or maybe there is a small amount of EDLF that is present
but not produced by these tissue basally. There is clearly complexity in EDLF production and it
is likely that only certain cells have the synthetic machinery to produce steroids or EDLF.
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Placenta is made up of particular layers of tissue with several cell types, each unique in its
function. The placenta connects the developing fetus and the maternal circulation. Recent
evidence showed that most of the placental cholesterol which is important for fetal development
is synthesized by the fetus, in other words, by the cells on the fetal side of the placenta instead of
transporting cholesterol from the maternal side. Moreover, the placental barrier was found to be
impermeable to low-density lipoprotein (LDL) and other lipoprotein particles. Therefore,
offspring of hypercholesterolemic mothers generally have normal cholesterol levels at term birth,
whereas maternal cholesterol still remains at a high level20. According to these observations we
conclude that placental EDLF syntheses on fetal and maternal sides, if it exists on the maternal
side, are relatively independent. Also, because PE is a multi-factorial disorder involving vascular,
genetic and immunological factors and ketoconazole inhibits various cytochrome P-450dependent enzymes which participate in multiple bioactivation and metabolism steps, it is hard to
explain clearly why ketoconazole may induce a small increase of EDLF production on the
maternal side of the placenta at this point. However, the integrated effect of ketoconazole on
placental EDLF production is down-regulation if one combines the data of Figure 26 and 27. It
means that ketoconazole is an inhibitor of placental EDLF synthesis, and the synthetic pathway
of EDLF very likely shares some steps with steroidogenesis involving the cytochrome P-450dependent enzymes.
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Figure 28. Schematic representation of a human term placenta, showing fetal side and maternal side 21.

These results suggest strongly that the synthetic pathway for EDLF production can be
further elucidated. In addition, it may provide insights into how to interrupt EDLF production as
one considers possible future therapeutic approaches.

Effects of a potential steroid synthesis intermediate, 17-hydroxyprogesterone, on placental
EDLF production.
In addition to inhibition of EDLF production, one would predict that increasing the
availability of synthetic precursor molecules could increase synthesis, especially in comparison
with placental cultures that lack that precursor. If such a factor could be found whose presence
can increase EDLF production, this would strongly reaffirm that EDLFs are produced in the
placenta and may share synthetic steps with steroid synthesis. Increased synthesis may also
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support and enhance efforts to isolate and identify the EDLF of PE. Therefore, we were
interested in identifying at least one substrate that participates in EDLF synthesis. To this end,
we applied graded concentrations of 17-hydroxyprogesterone to placental tissue culture, which is
a potential steroidogenesis intermediate. There is evidence that placenta lacks the 17-hydroxylase
and 17-OH progesterone then bypasses that deficiency22. Figure 29 shows that 48 hr of 17hydroxyprogesterone treatment resulted in increased levels of EDLF released into the culture
media in a dose dependent manner (n=6, 48 hr control no 17-OH progesterone: 29.6 ± 4.3 nM
EDLF compared with the progressive effects of graded increasing concentrations of 17-OH
progesterone respectively, 48 hr 0.2 M 17-OH progesterone: 36.0 ± 1.06 nM, 48 hr 0.5 M 17OH progesterone: 37.6 ± 0.84 nM, 48 hr 1 M 17-OH progesterone: 44.0 ± 5.3 nM, 2 M 17OH progesterone: 49.1 ± 1.52 nM ouabain equivalents EDLF; p=0.03). In order to further
identify its role in the pathway, we did time-dependent experiments using the optimal
concentration (2 M). Control placental tissues maintained in the absence of 17hydroxyprogesterone showed that EDLF release increased with increasing incubation time (Also
shown in Chapter 4, Figure 23, n=5, 6hr: 87.6 ± 2.56 nM, 12 hr: 237.0 ± 6.92 nM, 24 hr: 393.2
±14.76 nM; 36 hr: 675.9 ± 26.89 nM, 48 hr: 813.8 ± 18.77 nM ouabain equivalents EDLF;
p<0.05). Moreover, addition of 17-hydroxyprogesterone into the culture media enhanced the
accumulation of EDLF and the effect was time dependent (Figure 30, n=5, 6 hr of 2 M 17-OH
progesterone: 126.0 ± 3.81 nM, 12 hr of 2M 17-OH progesterone: 283.0 ± 6.30 nM, 24 hr of 2
M 17-OH progesterone: 553.9 ± 33.62 nM, 36 hr of 2 M 17-OH progesterone: 950.0 ± 40.44
nM, 48 hr of 2 M 17-OH progesterone: 1324.3 ± 74.37 nM ouabain equivalents EDLF; p<0.05).
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Figure 29. Effect of 17-hydroxyprogesterone on human plancental EDLF production. Freshly collected human
placenta was dissected and incubated in buffered culture media for 48 hr in the absence or presence of graded
concentrations of 17-hydroxyprogesterone. The culture media was collected and the amount of EDLF released from
the tissue was measured using an RIA. The data show a progressive increase in EDLF production with higher 17hydroxyprogesterone concentration (n=6, p=0.03).
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Figure 23. Human plancental EDLF accumulation. Freshly collected human placenta was dissected and incubated
in buffered culture media for increasing time. The culture media was collected and the amount of EDLF released
from the tissue was measured using an RIA. The data show a significant and progressive increase in EDLF
production with longer incubation time (n=5, p<0.05).
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Figure 30. Effect of 17-hydroxyprogesterone on human plancental EDLF production vs time. Freshly collected
human placenta was dissected and incubated in buffered culture media for increasing time in the presence of 2M
17-hydroxyprogesterone. The culture media was collected and the amount of EDLF released from the tissue was
measured using an RIA. The data show a significant and progressive increase in EDLF production with longer
treatment time (n=5, p<0.05).

These results suggest strongly that 17-hydroxyprogesterone has a strong influence on
EDLF production and is possibly a substrate of the EDLF synthetic pathway or is converted into
a substrate of that pathway and EDLFs are potentially synthesized through the steps involving
17-hydroxyprogesterone (shown in Figure 3 in Chapter 1).
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Effects of hypoxia on placental EDLF production
PE is attended by many changes. Among those considered mechanistically important are
placental hypoxia, increased production of ROS, and greater levels of proinflammatory cytokines.
Consequently, there was interest in knowing the effects of such factors on EDLF production and
release. Because previous studies suggested that hypoxia contributes to the development of PE or
is an early feature of PE, we cultured placental tissues under low O2 conditions and then
measured EDLF levels released in the media by Digibind RIA. Figure 31 and 32 showed that
hypoxia minimally stimulated EDLF production and release into the culture media after both 24
hr and 48 hr incubation (n=6, 24 hr control normal O2: 59.4 ± 4.4 nM vs 24 hr low O2: 70.0 ± 6.6
nM ouabain equivalents EDLF; p=0.028, and n=6, 48 hr control normal O2: 29.2 ± 2.4 vs 48 hr
low O2: 34.6 ± 2.7 nM ouabain equivalents EDLF; p=0.13). While the changes were statistically
significant at 24 hr, they were not at 48 hr.
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Figure 31. Effect of 24 hr hypoxia on human placental EDLF production. Freshly collected human placenta was
dissected and incubated in buffered culture media under normoxia (21% O 2: 5% CO2/95% air) and hypoxia
conditions (2% O2/5% CO2/93% N2) for 24 hr. The culture media was collected and the amount of EDLF released
from the tissue was measured using an RIA. The data show increased EDLF amount released in response to low O 2
tension (n=6, p=0.028).
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Figure 32. Effect of 48 hr hypoxia on human placental EDLF production. Freshly collected human placenta was
dissected and incubated in buffered culture media under normoxia (21% O 2: 5% CO2/95% air) and hypoxia
conditions (2% O2/5% CO2/93% N2) for 48 hr. The culture media was collected and the amount of EDLF released
from the tissue was measured using an RIA. The data show increased EDLF amount released in response to low O2
tension (n=6, p=0.13).

These data indicated that placental hypoxia may be a weak stimulus of EDLF synthesis and
release. Despite the somewhat different statistical results between 24 hr and 48 hr incubation,
both showed EDLF increases, though modest, in human placental tissue culture under hypoxic
conditions. This is consistent with the finding that hypoxia stimulates a marked release of a
sodium pump inhibitor called hypothalamic inhibitory factor (HIF) from midbrain and adrenal in
Wistar rats23.
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Effects of hydrogen peroxide as a model ROS on placental EDLF production
Because oxidative injuries have been shown to be increased in PE and oxidative stress
continues to be thought to contribute to the pathogenesis of hypertension in PE, we hypothesized
that oxidative stress may be a potential stimulus of EDLF synthesis and release. Therefore, we
used hydrogen peroxide as a representative ROS that mediates oxidative stress, to treat placental
tissue in culture and assayed the media by Digibind RIA to reveal its effect on EDLF
concentrations. By analyzing specimens from five individual placentas treated with graded
concentrations of H2O2, we found that the effects of 24 hr H2O2 treatment on placental EDLF
production did not show a clear trend whereas 48 hr H2O2 treatment appeared to increase
placental EDLF levels. However, 5 nM of H2O2 appeared to be the optimal concentration to
induce EDLF production and release. This concentration resulted in approximately double the
quantity of the released EDLF compared with untreated culture media (Figure 33, n=5, 48 hr
control: 29.2 ± 2.4 vs 48 hr of 5 nM H2O2: 49.3 ± 5.8 nM EDLF equiv; p=0.009). In the media
treated with higher concentrations (10 nM, 20 nM) of H2O2, EDLF levels were equal or even
slightly, though not significantly, lower than those produced with 5 nM of H2O2 (n=5, 48 hr of
10 nM H2O2: 35.3 ± 4.6 nM EDLF equiv, p=0.001, and n=5, 48 hr of 20 nM H2O2: 45.5 ± 5.3
nM EDLF equiv; p=0.003).
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Figure 33. Effect of H2O2 on human placental EDLF production. Freshly collected human placenta was dissected
and incubated in buffered culture medium for 48 hr in the absence or presence of 5 nM of hydrogen peroxide. The
culture media was collected and the amount of EDLF released from the tissue was measured using an RIA. The data
show increased EDLF levels released in response to 5 nM H 2O2 (n=5, p=0.009).

These observations suggested that as what we predicted, H2O2 stimulates EDLF synthesis
and release. Its effects on EDLF production may be in a parabolic manner, or a saturating
manner, and concentrations higher than 5 nM of H2O2 may actually result in a slight fall off of
EDLF levels.

Effects of a PE related cytokine TNFα on placental EDLF production
Because research suggests that cytokines may play an important role in the pathogenesis of
preeclampsia and/or may be a result of generalized endothelial dysfunction, it was of interest to
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know if cytokines might be regulators of EDLF production. Therefore, we carried out
experiments using TNF, a cytokine highly studied and previously shown to be increased in
PE12, to test its effect on placental EDLF production. RIA data show that after 48 hr TNF
treatment, levels of EDLF released into the culture media increased and this effect was also
TNF dose dependent (Figure 34, n=6, 48 hr control: 19.8 ± 2.7 vs 48 hr of 20 nM TNF: 44.7
± 4.0 nM EDLF equiv, p=0.0004).

Figure 34. Effect of TNF on human plancental EDLF production. Freshly collected human placenta was dissected
and incubated in buffered culture media for 48 hr in the absence or presence of graded concentrations of TNF. The
culture media was collected and the amount of EDLF released from the tissue was measured using an RIA. The data
show a progressive increase in EDLF production with higher TNF concentration (n=6, ANOVA p=0.0004).
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These results suggested that TNF could increase levels of EDLF synthesis and release. In
addition, this finding is consistent with the observations that TNF causes systemic endothelial
activation and therefore may participate in several main symptoms of PE, such as hypertension,
renal dysfunction and a further exaggerated inflammatory response.

Placental ROS release
As demonstrated above, low O2 tension potentially and low concentrations of H2O2
significantly induced elevated EDLF levels from human placental tissue culture. In order to
further assess the role of these oxidative stresses on placental tissue modification in PE, we used
a lipid hydroperoxide immunoassay to quantify lipid peroxidation in culture media treated with
low O2 or H2O2. These lipid peroxides represent products of ROS and are considered to be a
clear demonstration of oxidative damage, thus indicating ROS activity at increased levels. Figure
35 (n=6, control normal O2: 5.85 ± 3.11 vs 48 hr low O2: 10.30 ± 5.72 M lipid hydroperoxide;
p=0.01) showed that hypoxia conditions induced higher levels of ROS lipid in the media than
normoxia conditions. The increase was ~2 fold. As expected with higher H2O2 concentrations
the higher the levels of lipid hydroperoxides (Figure 36, n=5, control no H2O2: 5.05 ± 2.69, 1 nM
H2O2: 6.62 ± 3.31, 5 nM H2O2: 9.17 ± 3.18, 10 nM H2O2: 11.43 ± 3.67, 20 nM H2O2: 13.13 ±
5.04 M lipid hydroperoxide; p<0.05), suggesting that addition of H2O2 in placental tissue
culture resulted in oxidative injuries. Moreover, lipid peroxidation for 2% O2 and 5 nM H2O2
were very comparable, the levels being slightly higher for low O2 than for 5 nM H2O2.
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Figure 35. 48hr hypoxia effect on placental ROS release. Freshly collected human placenta was dissected and
incubated in buffered culture media under normoxia (21% O 2: 5% CO2/95% air) and hypoxic conditions (2% O2/5%
CO2/93% N2) for 48 hr. The culture media was collected and the amount of lipid hydroperoxide released from the
tissue was measured using a kit. The data show significantly increased LPO amount released in response to low O 2
tension (n=6, p=0.01).
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Figure 36. 48hr H2O2 effect on placental ROS release. Freshly collected human placenta was dissected and
incubated in buffered culture for 48 hr in the absence or presence of graded concentrations of hydrogen peroxide.
The culture media was collected and the amount of lipid hydroperoxide released from the tissue was measured using
a kit. The data show a progressive increase in LPO levels with higher H 2O2 concentration (n=5, p<0.05).

Placental TNF release
In addition, we were also interested in studying the interaction of hypoxia and oxidative
stress on placental TNF production. Given that TNFα seemed to represent the strongest
stimulus for EDLF production, we wanted to determine if the effect of hypoxia or hydrogen
peroxide on EDLF were actually mediated by their generating higher levels of TNFα. Therefore,
we used a TNF immunoassay to measure TNF concentrations in culture media of human
placental tissues treated with either 48 hr low O2 or 48 hr H2O2 at graded concentrations. Figure
37 indicated that 48 hr low O2 treatment induces more TNF release than media incubated under

103

normoxic conditions (n=6, control normal O2:19.01 ± 10.16 vs 48 hr low O2: 126.80 ± 249.6
pg/ml TNF; p=0.03) whereas in Figure 38 there is not a significant increase of TNF release
with increasing graded concentrations of H2O2 treatment (n=5, control no H2O2: 15.13 ± 3.98, 1
nM H2O2: 18.61 ± 13.60, 5 nM H2O2: 14.95 ± 6.39, 10 nM H2O2: 15.83 ± 6.63, 20 nM H2O2:
13.50 ± 7.67 pg/ml TNF; p=0.90).

These data suggested that under hypoxia conditions, placental tissues release significantly
higher levels of TNF, maybe also other cytokines, and that H2O2 treatment of the tissue culture
under the concentrations used in the EDLF experiments did not significantly stimulate TNF
release.
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Figure 37. 48hr hypoxia effect on placental TNF release. Freshly collected human placenta was dissected and
incubated in buffered culture media under normoxia (21% O 2: 5% CO2/95% air) and hypoxia conditions (2% O2/5%
CO2/93% N2) for 48 hr. The culture media was collected and the amount of TNF released from the tissue was
measured using a kit. The data show increased TNF amount released in response to low O2 tension (n=6, p=0.03).
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Figure 38. 48hr H2O2 effect on placental TNF release. Freshly collected human placenta was dissected and
incubated in buffered culture for 48 hr in the absence or presence of graded concentrations of hydrogen peroxide.
The culture media was collected and the amount of TNF released from the tissue was measured using a kit (n=5,
p=0.90). There was no significant change in placental TNF release with H2O2 exposure.

Discussion
With an enriched source of EDLF-placenta- and a sensitive approach which could measure
EDLF levels in placenta- the radioimmunoassay employing Digibind, we achieved initial
experimental evidences to further verify that EDLFs were synthesized in placenta and this
synthetic pathway shared some steps with steroidogenesis pathway.
Ketoconazole, a general inhibitor of steroid synthesis, was demonstrated to reduce EDLF
placental production in a dose-dependent manner. Despite the slight increase of EDLF levels
presenting in maternal tissues, ketoconazole appeared to inhibit EDLF production in whole
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placenta. Also, the addition of 17-OH progesterone in the placental tissue culture media, which is
a potential intermediate of steroidogenesis, was demonstrated to result in an elevation of EDLF
production. This effect was dose-dependent and time-dependent. Moreover, the accumulation of
EDLF in the placental culture by time was enhanced by the treatment of 17-OH progesterone.
These findings suggested that EDLF synthesis and steroidogenesis share some steps involving
17-OH progesterone and enzymes inhibited by ketoconazole. Again, those are reliable evidences
supporting that EDLF biosynthetic pathway occur in the placenta. However, 17-OH progesterone
may affect EDLF product indirectly, e.g. it could act as a regulator rather than a substrate or be
converted into something that acts as a regulator and not a substrate.

In order to know more about EDLF synthetic pathway, more intermediates of steroid
pathway need to be identified, such as pregnenolone and/or progesterone. Once we obtain
sufficient data to determine or exclude candidates for EDLF synthetic intermediates / substrates,
the pathway could be established step by step.

In addition to EDLF synthesis, the regulation of EDLF in placenta was another
consideration of my research. Hypoxia, oxidative stress and cytokines, which are established
features of PE or perhaps even participants in PE, were hypothesized to be regulatory agents of
EDLF synthesis and release. Experimental data showed that hypoxia conditions of appropriate
time, addition of low concentrations of hydrogen peroxide, a represent of ROS, and TNF, a
represent of cytokines, could stimulate increase of EDLF placental production. Thus, we
concluded that hypoxia, hydrogen peroxide and TNF are regulatory agents up-regulating EDLF
synthesis and release. Probably we also could deduce that not only H2O2 and TNF, but other
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ROS and cytokines are stimuli of EDLF release. It should be noted that in the hypoxia
experiments, the control conditions were using 21% O2 which is its concentration in air.
However, diffusion of O2 into placental tissue would have been limited and consequently 21%
O2 may also represent a hypoxic state compared with in vitro placenta being perfused by blood.

Immunoassays indicated that hypoxia treatment of the placental tissue resulted in higher
ROS levels released into the culture medium. It means that hypoxia might regulate EDLF levels
by inducing oxidative stress in PE. Also, the observations that hypoxia conditions led to higher
TNF levels released into the placental tissue culture suggested that hypoxia might be
responsible for the alteration of TNF, or even other cytokines levels, in PE. However, addition
of hydrogen peroxide did not elevate TNF levels significantly, indicating that ROS and
cytokines might regulate EDLF productions through independent pathways.

Although we have identified the roles of H2O2 and TNF in EDLF synthesis and release
in placenta, the effects of other ROS and cytokines have still to be determined. Such studies
would provide more insights to understand the regulation of EDLF in placenta.

However, because preeclampsia is a multi-systemic disorder, our research only revealed
limited aspects of the disease. EDLFs are regulated by several agents and have impacts on
several factors as well. The in vitro placental tissue experiments could not reflect the whole story
occurred in PE. For example, endothelial dysfunction including alteration of cytokine levels has
an effect observed in maternal vascular system in PE and EDLFs likely play an important role in
vascular events in PE. Questions naturally arise: Do EDLFs mediate endothelial dysfunction and
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hypertension? Or are there independent pathways in the two systems-the vascular system and the
immune system? Since maternal vascular system is involved in EDLF events, why were very
low levels of these factors measured in maternal tissues in placenta? It is possible that factors
such as ROS or cytokines might stimulate maternal production. Perhaps PE placentas behave
differently. If placental maternal tissues cannot produce EDLF, considered as a possibility earlier
in this Chapter according to the data of ketoconazole experiments, how were EDLF translated
from fetal layer to maternal layer? Or are there any other sources of EDLF that exist? If so, do
the sources produce more EDLF than placenta? If so, probably we could isolate and identify
EDLFs more easily. Further work is needed to elucidate these questions.
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Chapter 6: Summary and Future Studies

During the past few decades, a large number of studies on preeclampsia have been performed
worldwide. However, the mechanisms responsible for its causes and pathogenesis, as well as the
prevention and treatment of the disorder, remain unclear due to the complexity of the syndrome.
According to current understanding of the pathogenesis of PE, it can be simplified to a two-stage
process. The placenta being predisposed to hypoxia is the highly variable first stage, and the
release of soluble factors resulting in many of the other observed symptoms is the following
stage. Multiple systems have been implicated in the development of PE, such as the immune
system, the cardiovascular system, the central nervous system and the renin-angiotensin system1.
Currently, many hypotheses have attempted to explain why PE occurs and have linked the
syndrome to the presence of various disorders, including endothelial cell injury, immune
rejection of the placenta, compromised placental perfusion, altered vascular activity, imbalance
between prostacyclin and thromboxane, decreased intravascular volume, disseminated
intravascular coagulation, uterine muscle stretch (ischemia), vitamin deficiency, increased
central nervous system irritability, genetic factors, etc. These indicate that PE is likely a multifactorial disease process or set of diseases and hence the study of PE is complicated.

As the most visible and consistent sign of PE, hypertension plays an important role in the
pathophysiology of PE as well as being the product of other earlier pathophysiologic processes.
For the studies of PE in our lab, EDLF, which was found to be at increased levels in the
circulation most preeclamptic women and thus potentially an important causative factor of the
hypertension in PE, was considered to be the main research focus. We were interested in its
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synthetic pathway, regulation and isolation, knowing these would be of great importance. Such
insights would be helpful in understanding the actual processes underlying PE, allow for the
development of antagonists of EDLF, and quite possibly improve current measurement and
therapy of PE. In order to clarify the mechanisms of EDLF synthesis and regulation in PE, we
needed an accurate approach to the measurement of EDLF levels in specimens and a rich source
of these factors to provide sufficient amounts to perform structural characterization and
molecular composition experiments in vitro.

Currently, my research in conjunction with other studies from our laboratory have
provided substantial evidence for increased serum concentrations of ELDF in essential
hypertension, animal models of hypertension and, most importantly for my work, in women with
PE. Substantial work, much of it described here, provides consistent evidence for the existence
and source of EDLF. In addition, we have developed a sensitive theranostic assay employing
Digibind to measure EDLF levels in women with PE that should allow for the determination of
which women will respond positively to Digibind therapy. This same assay also provided a
sensitive and selective tool and has been used here to measure EDLF levels in placental tissue
culture, placental homogenates and sera. More importantly, we have carried out initial
experiments to explore the regulation and synthetic pathway of EDLF, and obtained sufficient
data to begin to have an outline of the story.

Convincing experimental and clinical evidence support that Digibind effectively binds to
EDLF and blocks its activity in PE. For our research, Digibind was used as a tool to measure and
isolate EDLF. The radioimmunoassay we developed applies Digibind as the primary antibody to
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selectively bind EDLF or ouabain, and the content of EDLF in human sera, placental
homogenates or placental tissue culture could be determined through competition of EDLF with
a tritiated ouabain tracer. This method is critical because it is a fast and accurate way to quantify
EDLF content in in vitro specimens and it makes further studies of EDLF synthesis and
regulation possible. Moreover, it also provides a means to identify preeclamptic women who will
respond to the therapy using Digibind and facilitates determination of an appropriate therapeutic
dose of Digibind.

However, due to the discontinuation and high expense of Digibind, the exploitation of a
monoclonal substitute is needed. Although we have found one or more monoclonal anti-digoxin
antibodies which have relatively good affinity for EDLF, their standard curves using cold
ouabain with known graded concentrations showed that these Mabs did not as yet provide a high
enough change in counts of radioactivity to make them highly accurate. In their current form
they may not have the sensitivity for the measurement of serum EDLF content at least in normal
pregnant women. Therefore, further optimization of these antibodies or screening of additional
Mabs is still in process in our lab. Based on previous experimental data, the discovery of a
monoclonal replacement for Digibind is promising. The process of making such a Mab usable in
the clinical setting would require substantially greater work, including having all components
standardized and the overall assay compatible with automated instrument platforms as used in
hospitals and clinics. This becomes a commercial undertaking once a suitable antibody is
demonstrated.
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Finally, these Mabs have all been developed against digoxin. Clearly, Mabs specific to one
or more EDLFs would represent a marked improvement in having a true theranostic assay and
having accurate concentration determinations of specific EDLFs. This awaits unequivocal
chemical identification of the relevant EDLF or EDLFs.

Besides an effective approach to measure EDLF levels, we also need an enriched source of
EDLF to perform later studies. According to previous clinical data which demonstrated that
placenta has higher EDLF levels than serum, placenta was hypothesized to be a source of EDLF.
Our in vitro experimental data also reaffirmed that placental homogenates from women whose
pregnancies were complicated with PE have much higher EDLF levels than sera from PE women.
The levels of EDLF secreted from normal placental tissue culture were even comparable with
those in sera from PE women. Hence, we concluded that placenta is a source of EDLF and can
be used to study the synthetic pathway and regulation of the factors. Also, having a rich source
and/or the ability to accumulate EDLF should facilitate efforts to isolate sufficient quantities of
one or more of these factors to carry out more structurally definitive instrumental analyses
including MS, NMR and perhaps even x-ray crystallography. These latter two techniques
require substantial amounts of material and consequently it may require a long time to acquire
this much pure factor.

In addition, a method using Digibind to isolate EDLF from placenta was developed. RIA
data showed that an appropriately chosen ultrafiltration filter could isolate Digibind-bound
EDLF from placental homogenates and most EDLF could be released from its affinity binding
by altering pH. This opens up the possibility to isolate EDLF quite cleanly and then identify its
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actual structure. Knowing the structure of EDLF would also facilitate research into its synthetic
pathway and regulation, and hence the future development of antagonists for use in antihypertensive or PE therapy.

Since we already verified that placenta is a source of EDLF, the mechanisms of its synthesis
in placenta were then of considerable interest. We carried out placental culture experiments using
ketoconazole, a general inhibitor of steroidogenesis, and found that it also inhibited EDLF
synthesis in placenta. In addition, results from placental tissue culture experiments using 17hydroxyprogesterone indicated that it may be an intermediate or a substrate or converted into an
intermediate or substrate of the EDLF synthetic pathway in placenta. The cumulative EDLF
concentrations as a function of time were enhanced by the treatment of 17-hydroxyprogesterone.
These findings reaffirmed that EDLFs are synthesized in placenta. Furthermore, these also
provide evidence supporting that the EDLF synthetic pathway share steps of steroid synthetic
pathway, which may involve 17-hydroxyprogesterone and cytochrome P-450-dependent
enzymes. Hence, an outline of EDLF synthetic pathway could be drawn. However, one cannot
rule out that the effect of 17-OH progesterone was indirect. For example, 17-OH progesterone is
a known substrate for cortisol and consequently the tissue may convert the progesterone to
cortisol and cortisol may regulate the EDLF production. This will require other types of
experiments where the 17-OH-progesterone is labeled and shown to result in labeled EDLF or
experiments involving the direct application of cortisol to placental tissue and its effects
determined.
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Although these experiments support that EDLF is produced by the placenta and shares
synthetic features with the steroid synthetic pathway, the individual steps in the synthesis are still
unknown. Additional experiments that use agents that are specific inhibitors of individual
enzymes are needed for all possible known steroid synthetic enzymes. Where such agents do not
exist or as confirmatory experiments, the use of small inhibiting RNAs can transiently knock
down specific genes and their products. Such an approach could be used in this tissue placental
culture to probe the involvement of any of several enzymes.

If EDLF is going to be a contributor to the disease process of PE, then its relationship to
other factors considered currently to be very important in the onset and/or maintenance of PE is
essential. As mentioned above, a predisposing placenta is held to represent the first stage of
disease. The problem seems to arise by the placenta failing to produce syntyciotrophoblasts or
adequate quantities of these to remodel the maternal vasculature to provide an adequate blood
supply to the intervillous space. This results in a low oxygen, low nutrient environment for the
fetus and is thought to result in the production of ROS. These factors lead to vascular
endothelial damage and release of proinflammatory cytokines including TNFα. Do these factors,
representing potentially early events in PE, have effects on EDLF production, potentially leading
to its exerting a hypertensinogenic effect on the mother?

It has been known that hypoxia and oxidative stress are features of PE and many contend
contribute to PE. Therefore, we hypothesized that they induce clinical aspects of PE by
upregulating EDLF. Placental tissue culture and RIA experimental data verified that hypoxia,
possibly, and hydrogen peroxide, a typical ROS, lead to elevation in EDLF production and
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secreted levels. Interestingly, the increase of EDLF levels under 24 hr hypoxia conditions was
more pronounced than 48 hr. Also, 5 nM hydrogen peroxide treatment of cultured placental
tissues may have resulted in more increase of secreted EDLF levels than 10 nM and 20 nM.
While the differences were not statistically different, both of these higher concentrations
registered somewhat lower levels of EDLF in these experiments. We do not have an explanation
for either of these observations but perhaps the somewhat lower EDLF levels at 48 hr or with
higher hydrogen peroxide for 48 hr may compromise the integrity of the tissue.

The observations of the effects of hypoxia and ROS on EDLF release were consistent,
suggesting that they upregulate EDLF production. Only appropriate treatment of hypoxia and
oxidative stress could induce most EDLF release. Too long a time of hypoxia or too high a dose
of hydrogen peroxide may not lead to yet higher EDLF production. Furthermore, immunoassays
indicated that ROS release in placental tissue culture was elevated by hypoxia treatment. It
proved that in vitro hypoxia treatment of placental tissue culture we utilized cause additional
oxidative stress of the tissue with release of molecules modified by oxidative stress. Also, higher
levels of know products of ROS were measured in the placental tissue culture treated with higher
concentrations of hydrogen peroxide, confirming that hydrogen peroxide added into the placental
tissue culture represents an appropriate oxidative stress. These results verified the hypothesis that
hypoxia contributes to PE by inducing oxidative stress, and in turn increases EDLF release
according to our current results. There are of course other ROS. The exact combination of
factors present in the maternal circulation and their timing or more particularly the exact
combination of ROS and duration of each in the immediate vicinity of the placenta are still open
questions.

119

Cytokines are another important set of candidates thought to mediate several aspects of PE.
It was of interest to know if they regulate PE synthesis. Our data showed that TNF is a
significant stimulus of EDLF secreted from placental tissue in culture. This effect occurred in a
dose-dependent manner. Hence, the presence and increase in EDLF is also consistent with
previous findings that levels of cytokines were increased in PE perhaps as a consequence of
vascular endothelial dysfunction, which is another feature of PE. Elevated levels of cytokines
then could induce an exaggerated inflammatory response, another PE symptom. However, there
has never been an exhaustive evaluation of all cytokines in PE and certainly we have not carried
out experiments to determine if all inflammatory cytokines increase EDLF or to the same degree.

The primary obstacle for the studies on EDLF in PE has been their low quantities. After
indentifying regulatory agents which upregulate EDLF synthesis and release, we could use these
agents to increase EDLF production and make the identification of their structures more feasible.

PE is a syndrome and thus the effects of the agents discussed above may not be independent.
For example, recent evidence suggested that cytokines stimulate NADPH oxidases in the vessel
and kidney, an enzyme contributing to ROS production, which then directly or indirectly
promote vasoconstriction2. Some hypertensive stimuli, such as high salt and angiotensin II, also
promote ROS production. Hence vasoconstriction may lead to higher ROS. In order to elucidate
the relationship of the regulatory agents, we also tested TNF production in tissue culture treated
with hypoxic conditions or with hydrogen peroxide. The results showed that hypoxia induced
substantially higher release of TNF in the culture than from the normoxic control, whereas
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hydrogen peroxide did not cause significantly increased TNF release in placental culture. These
results suggest strongly that the effects of hydrogen peroxide on EDLF release are not due to the
intervening release of TNFα. Hypoxia clearly elevated TNFα but had little or no effect on
placental EDLF output. Again this suggests that both TNFα and hydrogen peroxide have
independent pathways for the increase in EDLF production. Neveretheless, while having this
provided important insight into EDLF regulation, the complete set of regulators and their
hierarchical importance remains to be determined.

The studies on EDLF in our lab have provided substantial evidence supporting that EDLF
exist in most PE women and are present at elevated levels, and that they are synthesized in
placenta but also potentially in other maternal tissues. We also obtained initial data to elucidate
the regulation and synthetic pathway of these factors. Future work is promising because we
already developed an accurate method to detect EDLF and also found an enriched source of the
factors. TNF is a typical cytokine. More cytokines will be tested to confirm the role of the
entire species in regulating EDLF production, such as IFN and IL-6. More candidates of the
regulatory agents will also be tested in the future, such as anti-angiogenic factors and
thromboxane, which were found to be at increased levels in the serum of women with PE and
thus were thought to contribute to the pathogenesis of the disease3, 4. The regulatory factors we
already identified also brought out some questions we need to figure out in the future. For
example, since we‟ve already known that TNF and hydrogen peroxide upregulate EDLF
production in placenta in individual pathways, based on the findings that oxidative stress
promotes endothelial dysfunction by several mechanisms5, and that TNF is a contributor to
endothelial dysfunction6, we are interested that if these pathways have some relationship directly
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or indirectly? If they do, how? Furthermore, as proposed above, in order to elucidate individual
steps in the synthetic pathway of EDLF in placenta, specific inhibitors of individual enzymes and
/ or siRNA inhibiting specific intermediate or substrate could be used. In addition, our laboratory
has carried out some initial experiments in analyzing the structures of EDLFs using mass
spectrometry. Once the structures of the factors have been identified, or even partially identified,
the screening of the specific Mab (s) anti-EDLF(s) which could replace Digibind and provide
good performance in the RIA might be easier. Obviously, a theranostic of PE would be
developed as well. Even though there remain many questions of the study on EDLF, with the
tools and the extremely encouraging results we have, we believe that the isolation, identification,
regulation and synthesis of EDLF will be elucidated in the near future.
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